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The precautionary principle lies at the heart of the institutional architecture of EU risk regulation; EU institutions 
are fully entitled to take the precautionary principle and its overarching tenets into due consideration when 
enacting risk management measures. This article analyses judicial review of EU risk regulation, focusing on cases 
where EU acts have been challenged for being too restrictive. It enquires to what extent the Court’s application 
of different standards may safeguard precautionary measures and do justice to the key role of the precautionary 
principle. It identifies two problematic aspects in the Court’s case law: these are associated with the increasing 
focus on (mere) administrative discretion and application of the “all relevant factors” test in direct actions for 
annulment, and the analysis of the precautionary principle under the umbrella of proportionality review in 
preliminary rulings. Against the background of this analysis, the article puts forward two arguments and advocates 
a clearer and fuller acknowledgment of the role of the precautionary principle in the Court’s case law. 
 
 
This article analyses judicial review of EU risk regulation, enquiring to what extent the Court’s 
application of different standards may safeguard precautionary measures and do justice to the 
key role and function of the precautionary principle. It focuses on cases where EU acts have 
been challenged for being too restrictive, encompassing direct actions for annulment and 
challenges through the preliminary reference procedure. Scientific uncertainty and recourse to 
the precautionary principle are at stake in all the cases under analysis; the thread in all cases is 
the risk manager’s focus on persisting uncertainties, reliance on the results of a prudential risk 
assessment and precautionary risk management. 
The precautionary principle lies at the heart of the institutional architecture of EU risk 
regulation. At a minimum, it enshrines the risk manager’s broad discretionary power to enact 
precautionary measures whenever uncertain risks may not meet the intended EU level of 
protection. Under a maximalist interpretation, the precautionary principle can be framed as an 
“inner limit” to the risk manager’s administrative discretion. Under this reconstruction, the risk 
manager is under a duty to take the overarching tenets of the precautionary principle into due 
consideration, in order to pursue a high level of public health and environmental protection.1 
In either case, when the risk manager has resorted to the precautionary principle and 
precautionary measures are challenged for being too restrictive, the Court cannot conduct 
substantive or quasi-substantive review. In other words, it can neither scrutinise whether 
                                                     
1 In this perspective, see the analysis of cases involving challenges to EU acts deemed insufficiently protective in 
Leonelli, “Judicial review of compliance with the precautionary principle from Paraquat to Blaise: quantitative 
thresholds, risk assessment and the gap between regulation and regulatory implementation”, forthcoming 21 
German Law Journal (2020). Whether taking into consideration the precautionary principle and its tenets should 
be framed as a discretionary power of the risk manager or as a duty (and, in the latter case, what the specific 
boundaries of this duty are) is irrelevant for the purposes of the present enquiry. Indeed, all cases analysed in the 
following sections involve EU precautionary measures challenged for being too restrictive. 
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hazards and risks2 have been conclusively proven, nor review the “quality” and “soundness” 
of the scientific evidence relied upon by the risk manager. Precautionary risk management must 
be safeguarded. 
The article identifies and highlights two problematic aspects in the Court’s procedural review 
of EU risk regulation. The first problem relates to direct actions for annulment. The Court’s 
starting point has consistently been the acknowledgment of the risk manager’s broad 
administrative discretion in cases involving complex technical-scientific evaluations, and the 
finding that only a manifest error of assessment may invalidate EU acts. However, in cases 
involving acts which are deemed too restrictive, more than administrative discretion is at stake; 
EU institutions are exercising their power to pursue enhanced levels of protection by resorting 
to the precautionary principle. 
The analysis illustrates how the Court has increasingly put the accent on (mere) administrative 
discretion, rather than on precautionary risk management. The role of the precautionary 
principle in the Court’s interpretation of the notion of legally relevant manifest errors of 
assessment3 has then been considerably reduced. This has gone hand in hand with an increasing 
application of the “all relevant factors” test. Under this strand of case law, the boundaries of 
the notion of a manifest error are no longer interpreted in light of the precautionary principle; 
rather, the Court has come to associate a manifest error of assessment with the risk manager’s 
failure to procedurally take all relevant factors at stake into account. The article deconstructs 
this evolution, emphasising that the Court’s review of whether “all relevant factors” have been 
taken into consideration is problematic in many respects. Most importantly, the 
acknowledgment of the risk manager’s broad administrative discretion in cases where the “all 
relevant factors” test is applied is insufficient to safeguard precautionary risk management. An 
expansion of this test results in quasi-substantive review of the evidence relied upon by the risk 
manager. This threatens precautionary risk management and undermines the risk manager’s 
power to have recourse to the precautionary principle. 
The second problematic aspect relates to preliminary rulings. The analysis shows that 
preliminary rulings on the validity of EU acts which are challenged for being too restrictive 
frame the question of a breach or misapplication of the precautionary principle in terms of an 
infringement of proportionality. While this is of course legally tenable, the two principles  
should arguably be analysed separately. A set of reasons militate in favour of an autonomous 
examination of the precautionary principle. Most importantly, an analysis of the precautionary 
principle under the umbrella of proportionality review can obscure the rationale of 
precautionary risk management, the risk manager’s reliance on a prudential risk assessment 
and his focus on persisting uncertainty, as emerging from the risk assessment stage. This cannot 
do justice to the scientific dimension of the precautionary principle and its key role under EU 
risk regulation. 
The first and second sections of the article set the ground for the enquiry. They provide an 
overview of the relevant notions, highlight the crucial importance of scientific uncertainty and 
the precautionary principle within EU risk regulation, analyse the relevant implications for 
judicial review and explore the complex relationship between the precautionary principle and 
                                                     
2 See infra section 1. 
3 For a reference to the notion of a “legally relevant” manifest error of assessment, see the Opinion of A.G. Kokott 
in Case C-343/09, Afton Chemical Limited v. Secretary of State for Transport, EU:C:2010:258, para 30. 
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proportionality. The third section focuses on Pfizer4 and Alpharma,5 which lay the foundations 
for the Court’s procedural standard of review and for an interpretation of manifest errors of 
assessment in light of the precautionary principle. The fourth section examines Afton 
Chemical,6 with a particular focus on the Opinion of the Advocate General. For the purposes 
of the enquiry, this case has twofold relevance. Not only does it shed light on the implications 
of analysing the precautionary principle under the umbrella of proportionality. It also 
exemplifies the rise of the “all relevant factors” test, paving the way for an examination of the 
problems associated with this standard of review. 
The fifth section analyses different coexisting strands. Against this overall backdrop, the sixth 
section draws all relevant conclusions. First, it suggests that in preliminary rulings involving 
challenges to acts which are deemed too restrictive the question of a breach or misapplication 
of the precautionary principle should be examined separately, rather than under the umbrella 
of proportionality review. This would do justice to the precautionary principle and its function 
under EU risk governance. Where questions surrounding a breach or misapplication of the 
precautionary principle and manifest errors of assessment are referred, the two should be 
addressed together; in any case, the question whether EU institutions have manifestly erred in 
their assessment should always be examined against the background of the precautionary 
principle. 
Secondly, the conclusive section argues that the Pfizer and Alpharma strand of procedural 
review is more faithful to the institutional architecture of EU risk regulation. The Court should  
always draw an explicit connection between administrative discretion and precautionary risk 
management; further, and crucially, it should always interpret the notion of a manifest error of 
assessment in light of the precautionary principle, as occurs under the Pfizer and Alpharma line 
of cases. This would effectively safeguard precautionary risk management and acknowledge 
the key function of the precautionary principle within the system of EU risk regulation. 
 
 
1. Scientific Uncertainty, Precautionary Risk Management and The 
Implications for Judicial Review of EU Risk Regulation 
 
The boundaries of risk regulation, as a field, are marked by the notion of scientific uncertainty. 
Uncertainties may emerge at different stages of risk assessment; this precedes risk management 
and consists in a technical-scientific evaluation of relevant risks.7 Uncertainty is ubiquitous in 
the field of risk regulation. Different forms of scientific uncertainty can be categorised as 
“hazard-related”, “risk-related” or “methodological” uncertainties.8  
                                                     
4 Case T-13/99, Pfizer Animal Health SA v. Council, EU:T:2002:209.  
5 Case T-70/99, Alpharma v. Council, EU:T:2002:210. 
6 Judgment in Case C-343/09, Afton Chemical, EU:C:2010:419, and Opinion of A.G. Kokott in Case C-343/09, 
Afton Chemical, cited supra note 3. 
7 See Art. 3(11) and 6(2) of Regulation (EC) 178/2002 of the European Parliament and of the Council of 28 Jan. 
2002 laying down the general principles and requirements of food law, establishing the European Food Safety 
Authority and laying down procedures in matters of food safety, O.J. 2002, L 31/1, the General Food Law 
(hereafter, “GFL”). 
8 For this categorisation and an in depth overview on the notion of scientific uncertainty, see Leonelli, 
Transnational narratives and regulation of GMO risks (Hart Publishing, forthcoming 2021). 
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In the first case, uncertainties relate to the existence or the specific nature of a “hazard”; this is 
defined as a biological, chemical or physical agent with the potential to cause adverse effects.9 
Ultimately, uncertainty persists as to the existence of a direct causal link between the 
(potentially hazardous) properties and characteristics of a product or process, on the one hand, 
and public health or environmental adverse effects, on the other.10 To put it differently, 
scientific evidence can neither conclusively prove nor exclude the existence of a hazard and of 
specific adverse effects. The factual background of Pfizer and Alpharma, analysed in the third 
section, provides an example. In these two cases, the available evidence could not provide 
conclusive scientific proof of a causal relationship between the use of antibiotics in animal 
feed, on the one hand, and the development of antibiotic resistance in humans, on the other. 
By contrast, in the case of “risk-related” uncertainties, the existence of a hazard and of potential 
adverse effects is uncontroversial. Uncertainties stem from the process of evaluation and 
(qualitative or quantitative) characterisation of the relevant risks; under risk regulation, the 
notion of “risk” refers to the probability of exposure to a hazard, or probability of adverse 
effects, and the severity of any relevant consequences.11 Risk-related uncertainties may refer to 
“exposures” or to “probabilities”.12  In the first respect, for instance, uncertainty as to exposure 
in real life conditions or multiple exposures may be at stake. In the second respect, available 
evidence may be regarded as insufficient for the purposes of a reliable qualitative or 
quantitative evaluation of probabilities. Diverging data may also cast doubts on the possibility 
to adequately evaluate probabilities. Case law in the field of pesticidal products, under analysis 
in the fifth section, shows how these forms of uncertainty may come into play. Where data gaps 
are identified, or the available data on exposures or probabilities is deemed insufficient or 
inadequate, regulators may refrain from authorising a pesticidal product or restrict its use 
through stringent risk management measures. 
Finally, the application of different scientific models and methods may yield (very) different 
results. This is where “methodological” uncertainties emerge; the decision to have recourse to 
specific methods might then be the object of controversy.13 Case law in the field of chemicals, 
analysed in the fifth section, sheds some light on methodological uncertainties and their 
relevance. 
The notion of scientific uncertainty plays a key role under EU risk regulation; adherence to 
“sound” science, by contrast, does not belong to the system of EU risk governance. For the 
purposes of the present analysis, the 2001 Communication from the Commission on the 
Precautionary Principle provides the most detailed overview of the notions of uncertainty, 
prudential risk assessment and precautionary risk management, emphasising their crucial 
relevance within the EU risk regulation system. As the Communication clarifies, a prudential 
approach to risk assessment postulates that uncertainties emerging from all stages of the risk 
                                                     
9 See for instance COM(2000)1 Final, Communication from the Commission on the Precautionary Principle, 
Annex III, p. 28. 
10 Leonelli, op. cit. supra note 8. It is worth adding that uncertainties may also relate to hazard characterisation, 
i.e. the qualitative or quantitative determination of the nature and severity of the relevant adverse effects. On this 
stage, see Communication on the Precautionary Principle, Annex III, p. 28. 
11 See for instance Communication on the Precautionary Principle, Annex III, p. 28. For a detailed overview, see 
Leonelli, op. cit. supra note 8. 




assessment process should be taken into due consideration and be expressly addressed in the 
final findings.14  
“Hazard-related” and “risk-related” uncertainties should thus be clearly conveyed by risk 
assessors, with a view to adequately informing the technical-scientific knowledge of the risk 
manager and enabling him to take precautionary action, if warranted. Further, where the 
characterisation of hazards and risks is at stake and (“methodological”) uncertainties emerge, 
risk assessors should apply “prudential” methods and models and the risk manager should rely 
on these results; these methods are the ones which are more likely to over-estimate (rather than 
under-estimate) the relevant hazards and risks. As the Communication expressly mentions, 
“when the available data are inadequate or non-conclusive, a prudent and cautious approach 
[…] could be to opt for the worst case hypothesis”.15  
The application of the precautionary principle, on the other hand, is part of risk management. 
This stage consists in the political determination of the threshold of acceptable risk and 
subsequent enactment of risk management measures, weighing and balancing all relevant 
interests and taking alternative risk governance measures into account.16 The precautionary 
principle and the principle that a high level of public health and environmental protection shall 
be pursued in the Union are enshrined in the Treaties and all legislative frameworks in the field 
of EU risk regulation.17 However, yet again, this section will take a closer look at the more 
detailed definition laid out in the Commission Communication.  
As noted in the Communication, the precautionary principle encompasses two limbs. The 
former consists in the decision to act or not to act; the latter involves a decision as to how to 
act, i.e. the enactment of specific risk management measures.18 Starting from the decision on 
“whether to act”, the Communication stipulates that the precautionary principle may (or 
should) apply where “scientific information is insufficient, inconclusive, or uncertain and 
where there are indications that the possible effects on the environment or human, animal or 
plant health may be potentially dangerous and inconsistent with the chosen level of 
                                                     
14 On this point, see the reference in Communication on the Precautionary Principle, p. 13, sub-section 5.1.2. 
15 Communication on the Precautionary Principle, p. 28, Annex III. 
16 See Art. 3(12) and 6(3) of the GFL cited supra note 7. 
17 In the Treaties, see Art. 191(2) TFEU. In legislative acts, see inter alia recital (21), art. 6(3) and art. 7(1) of the 
GFL cited supra note 7; recital (8), art. 1(1) and art. 4(1) of Directive 2001/18/EC of the European Parliament and 
of the Council of 12 Mar. 2001 on the Deliberate Release into the Environment of Genetically Modified 
Organisms and Repealing Council Directive 90/220/EEC,  OJ 2001, L106/1 (“Deliberate Release Directive”); the 
cross-reference to the GFL in art. 7(1) of Regulation (EC) 1829/2003 of the European Parliament and of the 
Council of 22 Sept. 2003 on Genetically Modified Foods O.J. 2003, L 268/1 (“GM Food and Feed Regulation”); 
recital (8), and arts. 1(4) and 13(2) of Regulation (EC) 1107/2009/EC of the European Parliament and of the 
Council of 21 Oct. 2009 Concerning the Placing of Plant Protection Products on the Market and Repealing Council 
Directives 79/117/EEC and 91/414/EEC, OJ 2009, L 309/1; and recital (9) and (69) and art. 1(3) of Regulation 
(EC) 1907/2006 of the European Parliament and of the Council of 18 Dec. 2006 concerning the Registration, 
Evaluation, Authorization and Restriction of Chemicals (REACH), Establishing a European Chemicals Agency 
(ECHA), amending Directive 1999/45/EC and repealing Council Regulation (EEC) 793/93 and Commission 
Regulation (EC) 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 
93/67/EEC, 93/105/EC and 2000/21/EC, O.J. 2006, L 396/1 (“REACH”). References to the principle that a high 
level of public health and environmental protection shall be ensured are ubiquitous in legislation and in the 
Treaties (starting from Art. 114(3) and 191(2) TFEU).  
18 Communication on the Precautionary Principle, p. 12, section 5. 
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protection”.19 The precautionary principle thus applies when, in the face of persisting 
uncertainty, a risk may be too high to comply with the EU intended level of protection. 
An analysis of the definition enshrined in the Communication triggers two considerations. 
First, it is worth emphasising that this definition has a broad scope of application and may 
encompass all (“hazard-related”, “risk-related” and “methodological”) forms of uncertainty, as 
illustrated above in this section. Uncertainty may surround the existence as well as the extent 
or magnitude of a risk; indeed, the Communication clarifies that “the precautionary principle 
is relevant […] in the event of a potential risk, even if this risk cannot be fully demonstrated or 
quantified or its effects determined […]” (emphasis added).20 
Secondly, this definition shows that recourse to the precautionary principle entails the exercise 
of discretion in several respects: in the evaluation of the kind and extent of uncertainty 
triggering application of the principle, in the determination of the intended level of protection 
in a specific field and in the final decision that, having regard to the intended level of protection, 
a specific risk is too high to meet the threshold of acceptable risk and precautionary action is 
warranted.21 In this respect, the Communication expressly acknowledges that the decision on 
whether to act is the result “of an eminently political decision, a function of the risk level that 
is acceptable to the society on which the risk is imposed” (emphasis added).22 This lies at the 
heart of the institutional framework of EU risk governance, wherein functional expertise shall 
be complemented by political-democratic legitimacy.23 
What are the relevant implications for judicial review of EU risk regulation? As the following 
sections show, scientific uncertainty and scientific pluralism trigger multiple disagreements as 
to the scientific substantiation of the final risk management measures. The decision to employ 
prudential methods and models, yielding specific results, might also be the object of 
controversy. These disagreements will feed into complaints on manifest errors of assessment 
and alleged breaches or misapplication of the precautionary principle.  
In cases involving acts which are deemed too restrictive, the Court should not deploy a 
substantive or quasi-substantive standard of review. It should neither review whether the 
relevant hazards and risks have been conclusively proven, nor scrutinise the “quality” and 
“soundness” of the scientific evidence relied upon by the risk manager; in other words, the 
Court should not be in a position to directly or indirectly replace the risk manager’s evaluation 
of uncertain risks and identification of the threshold of acceptable risk.24 Different forms of 
                                                     
19 Ibid., p. 7, section 1, and p. 12, section 5. 
20 Ibid., p. 13, sub-section 5.1. 
21 On this point, see also Leonelli, op. cit. supra note 1; even where the precautionary principle is framed as an 
“inner limit” to the risk manager’s broad discretion, a distinction must be drawn between compliance with the 
duty to take into due consideration the precautionary principle and its tenets, on the one hand, and the risk 
manager’s exercise of discretion in complying with this duty, on the other. 
22 Communication on the Precautionary Principle, p. 15, sub-section 5.2.1. 
23 See COM(1997)176 Final, Commission Communication on the General Principles of Food Legislation in the 
European Union; COM(1997)183 Final, Commission Communication on Consumer Health and Food Safety; and 
COM(1999)719 final, White Paper on Food Safety. See also Case T-13/99, Pfizer, para. 149, as further explained 
infra in section 3. Under EU risk regulation, risk assessors only inform the technical-scientific knowledge of risk 
managers; the latter may at any time decide to disregard the positive results of a risk assessment, drawing different 
inferences and conclusions from the available data or referring to alternative scientific evidence. 
24 For an argument in favour of substantive review by the Court of the risk manager’s adherence to sound science, 
see Alemanno, annotation of Case C-77/09, Gowan Comércio Internacional e Servicos Lda v. Ministero della 
Salute, EU:C:2010:803, 48 CML Rev. (2011), 1329; Janssen and Van Asselt, “The precautionary principle in 
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uncertainty, high levels of scientific complexity and the risk manager’s power to resort to the 
precautionary principle when uncertain risks may not meet the intended EU level of protection 
call for limited judicial review of the factual evaluations underpinning risk management 
measures and of the exercise of administrative discretion in precautionary risk management. 
Ultimately, the Court should not directly or indirectly review the risk manager’s decision to 
focus on “hazard-related”, “risk-related” or “methodological” uncertainties, or indirectly 
scrutinise the level of protection which has been set in a specific field. Precautionary risk 
management must be safeguarded. 
The Court has consistently stated that, in cases involving complex technical-scientific 
evaluations, EU institutions enjoy a broad administrative discretion. Consequently, as the third 
section explains in further detail, only a finding that they have manifestly erred in their 
assessment will result in the annulment of an EU act which is deemed too restrictive. Yet, the 
notion of administrative discretion is differently framed in judicial review of EU risk 
regulation. As anticipated in the introductory section, some strands of case law put the accent 
on (mere) administrative discretion; a different line of cases, on the other hand, draws a clear 
connection between administrative discretion and the exercise of precautionary risk 
management. This results in a different interpretation of legally relevant manifest errors of 
assessment. As the analysis of the third, fourth and fifth sections illustrates, this has a set of 
substantive implications in judicial review of precautionary risk management measures. 
The final aspect to take into consideration in this section pertains to the “how to act” limb of 
the precautionary principle. This relates to the selection and enactment of specific risk 
management measures. The Communication states that precautionary risk management 
measures shall comply with general principles. These encompass proportionality, non-
discrimination, consistency, examination of the benefits and costs of action or inaction and 
examination of scientific developments.25 For the purposes of the present analysis, 
proportionality and the examination of costs and benefits are the most relevant principles.  
In respect of proportionality, the Communication provides that risk management measures 
must make it possible to achieve the appropriate level of protection; however, they should not 
be disproportionate to the desired level of protection. The Communication acknowledges that 
uncertainty may “considerably limit the number of options available to the risk managers”;26 
potential long-term, indirect or cumulative adverse effects must also be taken into account. 27 
A ban could thus be perfectly proportionate to the desired level of protection. As the next 
section explains, this suggests that the Court should take a highly deferential approach to 
proportionality review in the field of risk regulation. 
The requirement that an examination of the costs and benefits of risk management measures 
should be conducted overlaps with strict proportionality. The Communication mandates that 
an examination of the advantages and disadvantages associated with risk regulation should 
include an economic cost-benefit analysis where this is appropriate and possible.28 However, 
                                                     
Court. An analysis of post-Pfizer case law”, in Van Asselt, Versluis and Vos (Eds.), Balancing between Trade 
and Risk. Integrating Legal and Social Science Perspectives (Routledge, 2013), 197; Janssen and Rosenstock, 
“Handling uncertain risks: An inconsistent application of standards?” 7 EJRR (2016) 144. 
25 Communication on the Precautionary Principle, p. 7, section 6.3. 
26 Ibid., p. 17, sub-section 6.3.1. 
27 Ibid. 
28 Ibid., p. 19, sub-section 6.3.4. 
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as the Communication emphasises, the examination of the relevant advantages and 
disadvantages cannot be reduced to economic cost-benefit analysis; it is much wider in scope 
and shall include different considerations.29 Against this background, the economic cost-
benefit effectiveness of risk regulation, i.e. the enactment of regulatory measures which are 
expected to maximise aggregate wealth, is only one (and by no means the most relevant) factor 
to be taken into consideration at the risk management stage.30 Indeed, the precautionary 
principle encapsulates the risk manager’s discretionary power to find that, in the face of 
uncertainty and in light of the intended level of protection, collective public health and 
environmental benefits outweigh the individual economic costs to market actors. As the 
Communication concludes, “a society may be willing to pay a higher cost to protect an interest, 
such as the environment or health, to which it attaches priority”.31 
As anticipated in the introductory section, preliminary rulings involving acts which are deemed 
too restrictive frame the question of a breach or misapplication of the precautionary principle 
in terms of an infringement of proportionality. For this reason, the next section takes a closer 
look at the relationship and interconnection between the two principles. 
 
 
2.  The Precautionary Principle and Proportionality 
 
The relationship between the precautionary principle and proportionality is highly complex. 
Early case law did neither take into consideration a breach or misapplication of the 
precautionary principle, nor use it to determine the boundaries of the notion of a manifest error 
of assessment. This is unsurprising, given that the precautionary principle was only enshrined 
in the Treaties in 1992, at the time of the Treaty of Maastricht. Further, the Communication 
dates back to 2001, and the precautionary principle was only introduced in legislative 
frameworks in EU risk regulation in the 2000s. Early case law thus implicitly or obliquely took 
the precautionary principle into account when assessing the proportionality of risk management 
measures.32 In the following years, and still nowadays, preliminary rulings on the validity of 
EU legislative or regulatory acts which are deemed too restrictive have framed the question of 
a breach or misapplication of the precautionary principle in terms of an infringement of 
proportionality.33 Is there a perfect correspondence and symmetry between the two principles, 
though? 
                                                     
29 Ibid., p. 18, sub-section 6.3.4. The article does not take into consideration Other Legitimate Factors (“OLFs”), 
which also feed into the determination of the intended level of protection. For references to OLFs in EU 
legislation, see recital (19), art. 3(12) and art. 6(3) of the GFL cited supra note 7. See also recitals (9), (57), (58) 
and art. 31(7)(d) of the Deliberate Release Directive cited supra note 17, and recital (32) and art. 7(1) of the GM 
Food and Feed Regulation cited supra note 17. 
30 For a detailed overview, see Leonelli, op. cit. supra note 8. 
31 Communication from the Commission on the Precautionary Principle, p. 19, sub-section 6.3.4. 
32 See Case C-331/88, The Queen v. Minister of Agriculture, Fisheries and Food and Secretary of State for Health, 
ex parte: Fedesa and others (hereafter, “Fedesa”), EU:C:1990:391; Case C-157/96, Ex parte National Farmers’ 
Union and Others, EU:C:1998:191 (“BSE I”), particularly at paras 63 and 64; Case C-180/96, United Kingdom 
v. Council, EU:C:1998:192 (“BSE II”), particularly at para 99; Case T-199/96, Laboratoires Pharmaceutiques 
Bergaderm and Goupil v. Commission, EU:T:1998:176. 
33 See infra section 4. 
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Undoubtedly, an overlap exists between the two. Proportionality review encompasses a 
threefold examination.34 First, the Court will focus on whether a measure is suitable or 
appropriate to achieve its aim. Secondly, it will enquire whether the measure is necessary or 
whether less restrictive means (less burdensome measures) could have been used to achieve 
the same aim. Thirdly, it will analyse whether the measure is excessive. The last prong, strict 
proportionality, entails an evaluation of whether the means go beyond the aim. In judicial 
review of EU risk regulation, strict proportionality has on some occasions been analysed from 
two different angles: whether the disadvantages are disproportionate to the aim pursued, and 
whether they are disproportionate to the specific advantages associated with the regulatory 
measure (stricto sensu economic cost-benefit analysis).35 
As explained in the previous section, the precautionary principle encompasses a “whether to 
act” and a “how to act” limb. The analysis of both limbs can be absorbed within proportionality 
review. An examination of relevant case law shows that the applicants or referring courts have 
raised the point of suitability-appropriateness by pointing to lack of scientific proof of the 
existence or extent of specific risks; on these grounds, they have raised doubts as to whether 
the measures were appropriate to achieve public health or environmental protection.36 This 
pertains to the “whether to act” limb of the precautionary principle. On the other hand, 
complaints or questions surrounding the necessity of the measures or their excessive nature 
regard risk management measures and the “how to act” limb. 
Clearly, safeguarding precautionary risk management calls for a highly deferential review of 
proportionality. If a measure is deemed not appropriate to achieve its aim, the Court would 
ultimately be encroaching on the risk manager’s discretionary evaluation of whether uncertain 
risks meet the intended level of protection. If the Court finds that a risk management measure 
goes beyond what is necessary, or is excessive, the Court would still be encroaching on the 
determination of the intended level of protection and threshold of acceptable risk, for at least 
two reasons.  
The first reason is that other (less trade restrictive) measures may not be available or effective 
to meet the intended level of protection, so that the risks which are run in practice would turn 
out to be higher than the ones that the risk manager deemed acceptable. Indeed, the availability 
and efficacy of alternative risk management options are among the factors that the risk manager 
shall take into account when enacting precautionary measures.37 On these grounds, any finding 
that a measure goes beyond what is necessary is liable to affect precautionary risk 
management.38  
                                                     
34 Proportionality is only analysed in this article in so far as it overlaps with the precautionary principle. For a 
detailed overview of proportionality, see for all Tridimas, The general principles of EU law (OUP, 2006), and 
Turk, Judicial review in EU law (Edward Elgar, 2009). 
35 For this distinction in strict proportionality, see for instance Case T-13/99, Pfizer, para 407. 
36 See inter alia Case C-331/88, Fedesa; Case T-13/99, Pfizer, particularly at paras. 414 et seq., Opinion of A.G. 
Kokott in Case C-343/09, Afton Chemical, paras. 77 to 80, and Case C-78/16, Pesce and Others, EU:C:2016:428, 
paras. 57 et seq. (hereafter, “Xylella”). 
37 Under risk regulation, the availability and efficacy of risk management measures qualifies as an OLF that the 
risk manager may take into consideration. See for instance the reference in Communication from the Commission 
on the Precautionary Principle, p. 19, sub-section 6.3.4. 
38 For a clear example and acknowledgment of this point, see inter alia Opinion of A.G. Mischo in Case C-331/88, 
Fedesa, EU:C:1987:440, paras. 34, 35 and 39. 
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The second reason is that strict proportionality ultimately weighs and balances public health 
and environmental benefits vis-à-vis the economic costs which risk regulation imposes on 
market actors.39 This, however, is the form of economic cost-benefit analysis that, under the 
Commission Communication, need not inform precautionary risk management. In fact, a 
precautionary approach to risk management can hardly be cost-benefit effective. As an analysis 
of different models of risk regulation shows, the application of cost-benefit analysis heuristics 
goes hand in hand with adherence to “sound” science.40  Referring to what has been 
scientifically proven and established relieves market actors from the regulatory burdens and 
costs associated to precautionary regulation; this responds to the regulators’ pursuit of a cost-
benefit effective level of protection, wherein the expected benefits of risk governance outweigh 
the relevant economic costs. Conversely, focusing on persisting uncertainties and pursuing 
enhanced levels of protection creates additional economic costs. In this light, finding that a 
measure is excessive suggests that the high level of public health and environmental protection 
pursued is unjustified in the lack of conclusive scientific evidence, on the one hand, and the 
measure’s impact on economic rights, on the other.41 Ultimately, an intrusive review of the 
proportionality of risk management measures can have the same effects as substantive review 
of the “soundness” of the scientific evidence relied upon by the risk manager.42  
Against this backdrop, and with a view to safeguarding precautionary risk management, the 
Court should take – and indeed has taken – a highly deferential approach to proportionality 
review. Are there any reasons then, in cases involving acts which are deemed to be too 
restrictive, to distinguish between the analysis of a breach or misapplication of the 
precautionary principle, on the one hand, and review of proportionality, on the other? Arguably, 
a set of reasons militate in favour of this distinction.  
When the applicants or referring courts raise the issue of compliance with the precautionary 
principle,43 they are pointing to the scientific basis and scientific substantiation of the relevant 
measures and to the “whether to act” limb of the precautionary principle. In fact, even when a 
breach or misapplication of the precautionary principle is not called into question but a manifest 
error of assessment is alleged, the applicants or the referring court are still pointing to the 
scientific basis of the relevant measures. On these grounds, scientific uncertainty and scientific 
matters are always at stake when a violation of the precautionary principle or a manifest error 
are alleged.  
On the other hand, when the issue of proportionality is raised, the applicants or the referring 
courts are pointing to the specific risk management measures enacted and the level of 
                                                     
39 Admittedly, strict proportionality and cost-benefit analysis are in relationship to risk management measures 
adopted on the basis of the precautionary principle as well as OLFs. For this reason, the finding that a risk 
management measure is excessive may not only have to do with the application of the precautionary principle, but 
also OLFs. In risk regulatory terms, quantitative cost-benefit analysis (the rule of aggregate wealth maximisation) 
is directly opposed to qualitative OLFs; for more information see Leonelli, op. cit. supra note 8. The analysis does 
not take this take this aspect into consideration in order to simplify the overview, and given that the focus of the 
article is on the precautionary principle.  
40 On this point, see Leonelli, op. cit. supra note 8. 
41 For a similar acknowledgment, see inter alia Opinion in Case C-331/88, Fedesa, para 42. 
42 In this respect, see the analysis of Joined Cases T-74/00, T-76/00, T-83/00 to T-85/00, T-132/00, T-137/00 and 
T-141/00, Artegodan and Others v. Commission, EU:T:2002:283 in sub-section 5.4. 
43 For the sake of clarity, again, reference is being made to actions where a breach of the precautionary principle 
is alleged in so far as an act is deemed to be too restrictive. 
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protection pursued by the regulator; thus, they are referring to the “how to act” limb of the 
precautionary principle. In other words, they are disputing the necessity of the specific risk 
management measures and challenging the enhanced level of protection that the measures 
pursue, on the grounds that it is not cost-benefit effective. The scientific basis of the measures 
does not directly come into play. 
From this perspective, at a conceptual level, it is both possible and beneficial to draw a 
distinction between the two forms of review. In terms of legal analysis, an examination of 
alleged breaches or misapplication of the precautionary principle under the umbrella of 
proportionality review has an important implication; it can easily obscure the relevance of the 
precautionary principle and its key role in the face of scientific uncertainty. In other words, as 
the fourth section shows, proportionality review can hardly do justice to the scientific 
dimension in which the precautionary principle is embedded. Lastly, and as the fourth section 
also shows, a contextual analysis of the precautionary principle and proportionality has one 
further effect. If the precautionary principle and proportionality are assessed together, the 
precautionary principle can no longer mark the boundaries of the Court’s review of manifest 
errors of assessment in scientific matters.44 
On these grounds, and despite their overlaps, the two principles should arguably be kept 
separate. A breach or misapplication of the precautionary principle should always be analysed 
autonomously, by reference to scientific matters and to the notion of scientific uncertainty; 
symmetrically, the precautionary principle should always be used to interpret the scope and 
boundaries of the risk manager’s alleged manifest errors of assessment in scientific matters.45 
Both sets of complaints, as explained above, relate to the “whether to act” part. Proportionality 
review, on the other hand, should always focus on risk management measures and on the “how 
to act” part.  
This draws a clearer distinction between complaints on the scientific substantiation of the 
measures, on the one hand, and complaints on the measures, on the other. In line with the 
interconnections and overlaps between the two principles, only manifest errors of assessment 
and manifestly disproportionate risk management measures should be sanctioned by the 
Court.46  This concludes the preliminary overview of scientific uncertainty, the precautionary 
principle and its relationship to proportionality. Against this overall backdrop, the next part of 
the article analyses the evolution of the Court’s procedural standard of review of EU risk 
regulation. The third section starts by examining the “twin” Pfizer and Alpharma cases, which 
set the foundations for the Court’s procedural standard of review. 
 
 
3. The Foundations of Procedural Review and the Role of the Precautionary 
Principle 
 
                                                     
44 See infra section 4. 
45 See infra sections 3 and 5. 
46 For the acknowledgment that a deferential review of precautionary measures goes hand in hand deferential 
review of proportionality, see also Turk, op. cit. supra note 34, at 136 and 145, and Anderson, “Contrasting models 
of EU administration in judicial review of risk regulation” 51 CML Rev. (2014) 424, at 434. 
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The famous Pfizer and Alpharma decisions47 were delivered on the same day, in 2002; thus, 
both Judgments follow the enactment of the Commission Communication on the Precautionary 
Principle. Both cases involved direct actions for the annulment of EU withdrawals of the 
authorisation of antibiotics used as growth promoters in animal feed. Both decisions reflect a 
shift from early proportionality review of EU risk regulatory measures to a new focus on the 
scientific evidence underlying risk management. “Scientification” of judicial review, as a trend, 
is by no means unique to EU law.48 Under EU case law, a procedural standard applies to the 
review of the scientific substantiation of risk management measures. Pfizer and Alpharma lay 
the foundations for the application of this standard. 
The first relevant consideration is that the Court’s procedural review builds on the 
acknowledgment of the risk manager’s broad discretionary powers in cases involving complex 
evaluations, including technical-scientific assessments. The acknowledgment of broad 
administrative discretion was already apparent in the earlier strand of cases;49 however, it was 
elaborated further in Pfizer and Alpharma. When determining the level of risk deemed 
acceptable for society, EU institutions enjoy a broad discretion.50 Moreover, where EU 
institutions are required to make complex assessments, their discretion “also applies, to some 
extent, to the establishment of the factual basis of [their] action”.51 Therefore, risk regulation 
measures will only be invalid where the underlying scientific evaluations are vitiated by a 
manifest error of assessment, where the risk manager has misused its powers or where he has 
manifestly exceeded the limits of its discretion.52  
Broad administrative discretion as to the examination of the relevant facts and determination 
of whether uncertain risks meet the intended level of protection entails that the Court cannot 
substitute its evaluations for the ones of the risk manager.53As explained in the first section, 
and as acknowledged in Pfizer and Alpharma, the Court cannot scrutinise the “quality” or 
“soundness” of the scientific evidence relied upon and substantiating the risk management 
measures, as would occur under a substantive standard of review.54 A manifest error in the 
examination of scientific evidence is all that could invalidate the measures. What is truly 
remarkable about Pfizer and Alpharma, however, is rather the role played by the precautionary 
principle. This brings us to the second relevant consideration. The acknowledgment of the risk 
manager’s broad administrative discretion, as such, is complemented in Pfizer and Alpharma 
                                                     
47 Case T-13/99, Pfizer, cited supra note 4, and Case T-70/99, Alpharma, cited supra note 5. Neither case was 
appealed. 
48 For an analysis of the science-based obligations laid out in the WTO Agreement on Sanitary and Phytosanitary 
Measures (“SPS Agreement”) and DSB’s standard of review, see Scott, The WTO Agreement on Sanitary And 
Phytosanitary Measures. A Commentary (OUP, 2009). 
49 See for instance the Opinion in Case C-331/88, Fedesa, para 12, citing para 25 of Case C-138/79, Roquette v. 
Council, EU:C:1980:249, and the Judgment in Case C-331/88, Fedesa, para 8. In the assessment of 
proportionality, the Opinion (para 13) refers to Case C-138/78, Stölting v. Hauptzollamt Hamburg-Jonas, 
EU:C:1979:46, para 25, and Case C-265/87, Schräder v. Hauptzollamt Gronau, EU:C:1989:803, para 22. The 
Judgment in Case C-157/96, BSE I, paras. 39 to 41, cites Case C-98/78 Racke v. Hauptzollamt Mainz, 
EU:C:1979:14. 
50 Case T-13/99, Pfizer, para 167, and Case T-70/99, Alpharma, para 178. 
51 Case T-13/99, Pfizer, para 168, Case T-70/99, Alpharma, para 179, as well as the case law cited therein. 
52 Case T-13/99, Pfizer, para 166, and Case T-70/99, Alpharma, para 177. 
53 Case T-13/99, Pfizer, para 169, and Case T-70/99, Alpharma, para 180, “the judicature is not entitled to 
substitute its assessment of the facts for that of [EU] institutions”. 
54 See e.g. Case T-13/99, Pfizer, para 393, “it is not for the Court to assess the merits of either of the scientific 
points of view argued before it and to substitute its assessment for that of [EU] institutions […]”. 
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by a strong assertion of the precautionary principle. Symmetrically, the notion of a manifest 
error of assessment is interpreted against the backdrop of precautionary risk management.  
The applicants in these cases alleged several manifest errors of assessment as well as a breach 
or misapplication of the precautionary principle.55 Crucially, the GC56 considered it appropriate 
to examine these pleas in law together, rather than analysing the precautionary principle under 
the umbrella of proportionality. On these grounds, the GC used the precautionary principle to 
draw the boundaries of a “manifest” error of assessment and establish its nature. 
The vast majority of the applicants’ complaints on manifest errors related to lack of scientific 
proof of specific adverse effects (development of antibiotic resistance in humans) associated 
with the use of antibiotics in animal feed, in so far as a causal relationship could not be 
scientifically established and relevant exposures and probabilities could not be quantified.57 
EU institutions, on the other hand, clearly drew on scientific controversies and disagreement 
as to the uncertain risks that the use of these substances in animal feed could pose, referencing 
studies on persisting uncertainty and the need to conduct further assessments. The GC 
examined whether EU institutions had manifestly erred in their findings, in light of the 
precautionary principle.58 
In Pfizer, the GC found that EU institutions had not disregarded or distorted the positive results 
of the Opinion delivered by the Scientific Committee; rather, they had drawn different 
inferences and conclusions from all the available scientific data, taking the margins of scientific 
uncertainty into account. On these grounds, and without incurring any manifest error, “they 
concluded that […] they had a proper scientific basis for taking action under the precautionary 
principle”.59 Similarly, when examining Pfizer’s allegations on the absence of proof of a causal 
link between use of the products and development of antibiotic resistance, the GC noted that 
Pfizer could not reasonably criticise the institutions for basing themselves on “scientific studies 
which [do] not admit of scientific certainty”.60 This is inherent to the logics of the precautionary 
principle, so that persisting uncertainties and the impossibility to carry out a quantitative risk 
assessment do not prevent the competent authority “from taking preventive protective measures 
[…], regard being had to the level of risk […] which the authority has decided is the critical 
threshold […]”.61 Indeed, in the opposite case, the precautionary principle would be rendered 
devoid of purpose.62 
Similar considerations apply to Alpharma. The GC was adamant in remarking that the 
precautionary principle allows for consideration of scientific uncertainty, and more specifically 
the impossibility to determine the existence or the extent of a risk in the lack of conclusive 
                                                     
55 Case T-13/99, Pfizer, para 107 (as two separate pleas in law), and Case T-70/99, Alpharma, paras. 99 and 100 
(as a single plea in law). 
56 For the sake of clarity, in cases decided by the Court of First Instance reference is made to the General Court 
(“GC” in the text). 
57 Case T-13/99, Pfizer, paras. 312 et seq. and 347 et seq., and Case T-70/99, Alpharma, paras. 99 and 100. 
58 Throughout these two Judgments, it is very common to find references to the manifest errors alleged by the 
applicants followed by references to the precautionary principle. See for instance Case T-13/99, Pfizer, para 170, 
and Case T-70/99, Alpharma, para 181.  
59 Case T-13/99, Pfizer, paras. 231 and 246. 
60 Case T-13/99, Pfizer, para 383. 
61 Ibid., para 382. 
62 Case T-13/99, Pfizer, para 386, and Case T-70/99, Alpharma, paras. 173 and 282. 
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scientific evidence.63 Thus, in a situation in which the precautionary principle is applied and 
“which by definition coincides with a situation [of uncertainty], a risk assessment cannot be 
required to provide [EU] institutions with conclusive scientific evidence of the reality of the 
risk and the seriousness of the potential adverse effects […]”.64  On these grounds, the GC 
found in both cases that the institutions had sufficient scientific grounds to conclude that 
uncertain risks existed and that they exceeded the threshold of acceptable risk; thus, they had 
not committed any manifest errors.  
What are, then, the procedural limits to the risk manager’s exercise of his discretionary powers 
in the enactment of precautionary measures? The identification of these limits, which are also 
the object of the GC’s procedural review, is the third contribution of Pfizer and Alpharma. In 
these two cases, compliance with the procedural preconditions for the exercise of 
administrative discretion is framed in terms of a general obligation to conduct a comprehensive 
risk assessment.65 The competent authority must ensure that risk management measures are 
based on “as thorough a scientific risk assessment as possible […]”;66 it must have “sufficiently 
reliable and cogent information to allow it to understand the ramifications of the scientific 
question raised”67 and “sufficient scientific indications to conclude on […] a scientific basis” 
that uncertain risks are not acceptable.68 In this sense, as famously acknowledged, “a scientific 
risk assessment carried out as thoroughly as possible on the basis of scientific advice founded 
on the principles of excellence, transparency and independence is an important procedural 
guarantee whose purpose is to ensure the scientific objectivity of the measures adopted and 
preclude any arbitrary measures” (emphasis added).69 The question of arbitrariness is also 
connected to the distinction between scientific uncertainty, on the one hand, and hypothetical 
risk, on the other. The uncertain risks that the risk manager identifies and considers above the 
threshold of “acceptable risk” cannot be mere hypothetical risks. Thus, as the GC held in both 
cases, a precautionary measure cannot “be based on a purely hypothetical approach […], 
founded on mere conjecture which has not been scientifically verified. Rather, […] [a 
precautionary measure] may be taken only if the risk, although the reality and extent thereof 
have not been fully demonstrated by conclusive scientific evidence, appears nevertheless to be 
                                                     
63 Case T-70/99, Alpharma, para 164. See also para 174 therein. 
64 Case T-13/99, Pfizer, para 142, and Case T-70/99, Alpharma, paras. 153 to 155, as well as the case law cited 
therein. 
65 See Case T-70/99, Alpharma, para 183. Pfizer takes a more “restrictive” perspective on the scientific standard 
of proof and scientific substantiation of the relevant measures; however, it is necessary to stress that these have 
remained isolated statements, on which the Court has not drawn in following years. See for instance Pfizer, para 
198, “the competent [EU] institution must, first, prepare for [the experts] the factual questions which need to be 
answered before it can adopt a decision and, second, assess the probative value of the opinion delivered […]. In 
that regard, the [EU] institution must ensure that the reasoning in the opinion is full, consistent and relevant”, and 
para 199, “to the extent to which the institution opts to disregard the opinion, it must provide specific reasons for 
its findings by comparison with those made in the opinion and its statement of reasons must explain why it is 
disregarding the latter. The statement of reasons must be of a scientific level at least commensurate with that of 
the opinion in question. In such a case, the institution may take as its basis either a supplementary opinion from 
the [experts] or other evidence, whose probative value is at least commensurate with that of the opinion 
concerned”. For a similar perspective, see also Joined Cases T-74/00, T-76/00, T-83/00 to T-85/00, T-132/00, T-
137/00 and T-141/00, Artegodan and Others v. Commission, paras. 199 and 200. 
66 Case T-13/99, Pfizer, paras 162 and 165, and Case T-70/99, Alpharma, para 175. 
67 Case T-13/99, Pfizer, para 162, and Case T-70/99, Alpharma, para 175. 
68 Case T-13/99, Pfizer, para 165. 
69 Case T-13/99, Pfizer, para 172 and also 159, and Case T-70/99, Alpharma, para 183 and also 172. 
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adequately backed up by the scientific data available […]”.70 On these grounds, procedural 
review strikes a balance between the risk manager’s broad discretionary power to set the 
intended level of protection and take precautionary action, and the need to check compliance 
with the procedural conditions for the exercise of this power. 
The final consideration relates to proportionality.71 In the wake of the Commission 
Communication, Pfizer and Alpharma have drawn a clearer distinction between review of the 
scientific substantiation of risk management measures and review of risk management 
measures, manifest errors of assessment and proportionality. These cases testify that the more 
the Court’s review of scientific substantiation expands, the more proportionality review 
shrinks. Unsurprisingly, the GC’s deferential procedural review of science in Pfizer and 
Alpharma has gone hand in hand with a deferential approach to proportionality review.72 
Against this overall backdrop, and to draw some conclusions, Pfizer and Alpharma have played 
a key role in the elaboration of the Court’s procedural standard for the review of scientific 
evidence. By tying administrative discretion, the precautionary principle and the notion of a 
manifest error of assessment together, these cases have emphasised the interconnections 
between these three elements. In this sense, the acknowledgment of the crucial role of the 
precautionary principle under EU risk regulation reinforces the broad administrative discretion 
of the risk manager and qualifies its scope, assisting the Court in the interpretation of the notion 
of a “manifest” error. Further, it sheds light on the institutional dynamics underlying EU risk 
regulation and the delicate balance between democratic legitimacy and technical expertise.73 
As the fifth section shows, a strand of more recent cases follows the Pfizer and Alpharma 
standard of review and interpretation of the notion of a manifest error of assessment. The next 
section, on the other hand, turns to an analysis of Afton Chemical. This paves the way for the 
following examination of coexisting strands.  
 
 
4. Proportionality Review in Preliminary Rulings and the Rise of the “All 
Relevant Factors” Test 
 
The following stage in the case law has marked a development in the Court’s procedural 
standard of review. The Court’s examination of whether the risk manager has incurred a 
manifest error has come to be increasingly disassociated from the broader context of 
                                                     
70 Case T-13/99, Pfizer, paras 143 and 144, and Case T-70/99, Alpharma, paras 156 and 157. 
71 In Pfizer, see paras. 405 et seq.; in Alpharma, see paras. 320 et seq., particularly paras. 325, 338, 349 and 363. 
72 Case T-13/99, Pfizer, para 412 et seq., and Case T-70/99, Alpharma, para 325 et seq. 
73 See Pfizer para 151, and Alpharma para 164: “[…] it is for the [EU] institutions to determine the level of 
protection which they deem appropriate for society. It is by reference to that level of protection that they must 
then […] determine the level of risk — i.e. the critical probability threshold for adverse effects on human health 
and for the seriousness of those possible effects — which in their judgment is no longer acceptable for society 
[…]. Therefore, determining the level of risk deemed unacceptable involves the [EU] institutions in defining the 
political objectives to be pursued under the powers conferred on them by the Treaty”. See also Pfizer para 201: 
“that finding can also be justified on grounds of principle relating to the political responsibilities and democratic 
legitimacy of the Commission. Whilst the Commission's exercise of public authority is rendered legitimate […] 
by the European Parliament's political control, [technical experts], although they have scientific legitimacy, have 
neither democratic legitimacy nor political responsibilities. Scientific legitimacy is not a sufficient basis for the 
exercise of public authority”. 
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precautionary risk management; in these cases, the Court sets its analysis against the different 
backdrop of the risk manager’s broad administrative discretion. 
This incremental evolution in the case law is probably most clearly exemplified by the Opinion 
of Advocate General Kokott and the ECJ’s Judgment in Afton Chemical.74 In this case the ECJ 
was called upon to deliver a preliminary ruling on the validity of limits for the use of a metallic 
additive for motor vehicles fuel; the limits had been imposed pending the development of a test 
methodology, which would allow for an adequate and comprehensive risk assessment. Clearly, 
the need (and temporary impossibility) to conduct a thorough risk assessment, uncertainty as 
to the extent of the public health risks posed by the use of this metallic additive and the 
precautionary principle were at stake in this case. The national court referred questions on the 
alleged invalidity of the act as being based on a manifest error of assessment, a breach of the 
precautionary principle and a breach of proportionality. 
Afton Chemical has twofold relevance and triggers two sets of considerations. First, in the 
Opinion in this preliminary ruling, Advocate General Kokott did not examine the questions on 
a manifest error of assessment and alleged breaches of the precautionary principle together. 
Indeed, since the beginning of her analysis, she found that the emphasis of the questions was 
“on the principle of proportionality, in the framework of which the precautionary principle […] 
[is] also relevant”.75 In examining the precautionary principle and proportionality together, the 
Advocate General drew on early case law (the Fedesa strand)76 as well as preliminary rulings 
delivered in the previous years. In these preliminary rulings on the validity of acts challenged 
for being too restrictive, the ECJ took the precautionary principle into consideration in the 
examination of questions surrounding proportionality. As a result, the two principles were 
analysed together.77 However, it is worth highlighting that these preliminary references, with 
two partial exceptions,78 did not include specific questions on manifest errors or an alleged 
breach of the precautionary principle. The questions of the referring courts largely focused on 
proportionality, so that the precautionary principle was mentioned by the ECJ in the only 
context where it could fit. Nor were scientific uncertainty and the precautionary principle 
                                                     
74 Opinion of A.G. Kokott in Case C-343/09, Afton Chemical, cited supra note 3, and Judgment in Case C-343/09, 
Afton Chemical, cited supra note 6. It is worth noting that the Court had in other cases before Afton Chemical 
employed the “all relevant factors” test; see for instance Case T-75/06, Bayer CropScience and Others v. 
Commission, EU:T:2008:317 (hereafter, “Bayer CropScience I”), and Case C-425/08, Enviro Tech Europe, 
EU:C:2009:635 (hereafter, “Enviro Tech I”), both analysed in sub-section 5.1. Incidental references to the duty 
of the competent institution to examine carefully and impartially all the relevant aspects of the individual case can 
also be found in Pfizer, at para 171, and Alpharma, para. 184. However, the Opinion in Afton Chemical 
exemplifies this shift in a much clearer way. 
75 Opinion, para 25. 
76 See supra note 32. 
77 Case C-453/03, ABNA and Others, EU:C:2005:741; Case C-154/04, Alliance for Natural Health and Others, 
EU:C:2005:449; Case C-504/04, Agrarproduktion Stebelow, EU:C:2006:30; Case C-448/06, cp-Pharma, 
EU:C:2008:418; Case C-558/07, S.P.C.M. and Others, EU:C:2009:430; Case C-425/08, Enviro Tech I, cited 
supra note 74. See also the references to the precautionary principle in the context of proportionality in the first 
tobacco rulings; Case C-491/01, British American Tobacco, EU:C:2002:741, and Case C-434/02, Arnold André, 
EU:C:2004:800.  
78 The first exception is Case C-453/03, ABNA and Others; however, scientific uncertainty and the precautionary 
principle “stricto sensu” were hardly at stake in this case. The second exception is Case C-425/08, Enviro Tech I. 
In this case, analysed in sub-section 5.1, uncertainty and precautionary risk management were at stake. However, 
the ECJ found that the Commission had not resorted to the precautionary principle at all; for this reason, it did not 
assess whether the measures were in breach of the precautionary principle. 
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“stricto sensu”, as applicable to risk regulation and as distinguished from the general pursuit 
of a high level of public health, consumer or environmental protection, at stake in each and 
every of these cases. 
These considerations do not apply to Afton Chemical, where separate and specific questions on 
a manifest error of assessment, the precautionary principle and proportionality were referred. 
Further, scientific uncertainty and a “stricto sensu” application of the precautionary principle 
were directly at stake. The Advocate General merged review of a breach or misapplication of 
the precautionary principle and proportionality review; the ECJ followed the Opinion.79 This 
approach has entrenched in preliminary rulings where acts are challenged for being too 
restrictive; in these cases, unlike in direct actions for annulment, review of a breach or 
misapplication of the precautionary principle is always absorbed in the Court’s review of the 
proportionality of the final measures.80 This occurs regardless of whether specific questions on 
manifest errors or the precautionary principle have been referred and regardless of whether 
legislative or regulatory acts are at stake. 
In her overlapping assessment of the precautionary principle and proportionality, the Advocate 
General drew an analogy with the regulation of trade supplements,81 the Habitats Directive82 
and the regulation of chemicals,83 remarking that EU institutions can issue bans or set limits 
without (or pending) a comprehensive risk assessment.84 She found that uncertainty has an 
effect “on the manner in which the principle of proportionality is applied”,85 allowing for the 
adoption of protective measures, and that it is an authorisation (rather than a prohibition) which 
must be based on a comprehensive risk assessment.86 After an analysis of the three prongs of 
proportionality, she concluded that the legislative act at issue did not breach the principle; the 
ECJ largely followed the Opinion.   
Despite the acknowledgment of the risk manager’s broad discretion and the Court’s deferential 
review of proportionality, this case shows that an examination of the precautionary principle 
under the umbrella of proportionality cannot quite do justice to the former. In cases where 
scientific uncertainty and a “stricto sensu” application of the precautionary principle are at 
                                                     
79 It is worth adding that, in para 54 of the Opinion, A.G. Kokott found that “[…] Directive 2009/30 was adopted 
directly on the basis of Article 95 EC. A legislative measure of that sort cannot be directly assessed according to 
whether it observes the precautionary principle. However, the precautionary principle applies primarily in 
connection with the assessment of the principle of proportionality”. Yet, in some preliminary rulings where 
legislative acts adopted under the same legal basis (now Article 114 TFEU) are challenged for not being protective 
enough, the ECJ has examined alleged breaches of the precautionary principle autonomously. See Case C-528/16, 
Confédération Paysanne and others v. Premier Ministre and Ministre de l’Agriculture, de l’Agroalimentaire et 
de la Forêt, EU:C:2018:583, even though the ECJ did not need to address and answer the relevant question in this 
case; and Case C-616/17, Blaise and others, EU:C:2019:800. 
80 See Case C-77/09, Gowan, EU:C:2010:803; Case C-221/09, AJD Tuna, EU:C:2011:153; Case C-157/14, 
Neptune Distribution, EU:C:2015:823; Case C-78/16, Xylella, cited supra note 36. See also the new tobacco 
rulings, Case C-477/14, Pillbox 38, EU:C:2016:324; Case C-547/14, Philip Morris Brands and Others, 
EU:C:2016:325; Case C-151/17, Swedish Match, EU:C:2018:938. Again, not all of these preliminary rulings 
involved scientific uncertainty and a “stricto sensu” application of the precautionary principle. However, in either 
case, the latter principle is always mentioned or analysed in the context of proportionality review. 
81 Opinion, para 68. 
82 Opinion, para 70. 
83 Opinion, para 72. 
84 Ibid., paras. 67 and 69. 
85 Para 62. 
86 Para 70. 
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stake, a contextual analysis of the two principles obscures the rationale for precautionary risk 
management, the aims pursued by the risk manager and the key role of precaution. The 
scientific dimension of the precautionary principle, the relevance of different forms of 
uncertainty and the pursuit of enhanced levels of protection are not explicitly or fully addressed. 
Ultimately, the broader context of scientific uncertainty and the scientific basis for recourse to 
the precautionary principle are not explicitly or fully addressed.  
The analysis of alleged breaches of the precautionary principle overlaps with the (different) 
question of the necessity of risk management measures and with strict proportionality review; 
arguably, then, the analysis of the precautionary principle becomes “ancillary” to and is 
absorbed within proportionality review. In this sense, an examination of alleged breaches of 
the precautionary principle under the umbrella of proportionality does not do justice to the 
reasons why precautionary action is being taken. To a greater or lesser extent, this emerges 
from all preliminary rulings on the validity of EU risk regulation measures;87 it is also apparent 
from a comparison of these rulings with the analysis of the precautionary principle in cases like 
Pfizer and Alpharma. 
Turning to the second relevant aspect in Afton Chemical, the examination of the national court’s 
question on an alleged manifest error of assessment shows the “vacuum” left by the 
precautionary principle. How to set the boundaries of a “manifest” error, where this is not 
analysed in the context of precautionary risk management? The referring court’s question was 
developed on the grounds that the risks connected to the use of the metallic additive had not 
been investigated by means of a comprehensive risk assessment. The Advocate General 
remarked that “an error of assessment cannot, on its own, call into question the validity of [an 
act]. Rather, what matters is whether the error of assessment [is] legally relevant” (emphasis 
added).88  
This statement is of crucial importance. What is the legally relevant manifest error of 
assessment that the Advocate General referred to, and how should it be interpreted? Under the 
Pfizer and Alpharma strand, legally relevant manifest errors of assessment are the ones 
committed in so far as EU institutions have misapplied the precautionary principle; risk 
managers will incur these errors if they have not conducted as thorough a risk assessment as 
possible in the present circumstances and if they are referring to hypothetical risks. Had the 
Advocate General analysed the questions on manifest errors and the precautionary principle 
together, she would have arguably found that the EU legislator had neither committed legally 
relevant manifest errors nor misapplied the precautionary principle; in the face of insufficient 
data, and in so far as it was provisionally impossible to conduct a thorough risk assessment, 
precautionary measures were warranted.89 Indeed, waiting for the relevant risks to materialise 
would make the precautionary principle nugatory. 
By contrast, the Opinion in Afton Chemical sets the notion of legally relevant manifest error of 
assessment against a different background. The Opinion emphasises that EU institutions “[…] 
must be able to show before the Court that in adopting [an] act they actually exercised their 
discretion, which presupposes the taking into consideration of all the relevant factors and 
                                                     
87 For a more thorough engagement with the precautionary principle and its overarching tenets, albeit under the 
umbrella of proportionality review, see Case C-78/16, Xylella. 
88 Opinion, para 30. 
89 See supra section 3 and in particular Case T-13/99, Pfizer, para 160. 
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circumstances of the situation the act was intended to regulate” (emphasis added).90 Not only 
must the […] Courts, inter alia, establish whether the evidence relied on is factually accurate, 
reliable and consistent but also whether that evidence contains all the information which must 
be taken into account […] and whether it is capable of substantiating the conclusions drawn 
from it”.91  
The Opinion draws on the “all relevant factors” test;92 the exercise of the EU institutions’ broad 
discretionary powers presupposes the taking into consideration of all the relevant factors and 
circumstances of the situation that the act was intended to regulate. EU institutions, then, will 
incur a legally relevant manifest error of assessment if they fail to take into consideration all 
the relevant factors; in that case, they will have failed to comply with the procedural 
preconditions for the exercise of their broad discretion. In her Opinion, taking a deferential 
approach to review of administrative discretion, the Advocate General found that no errors of 
assessment had been incurred.93 The Court followed the Opinion. 
This different standard of procedural review triggers a set of considerations. First, the “all 
relevant factors” test has added a further layer of complexity to judicial review of EU risk 
regulation. Secondly, if compared to the Pfizer and Alpharma standard, it has considerably 
expanded the Court’s procedural scrutiny. Thirdly, this test builds on administrative discretion 
and an analysis of the procedural preconditions for its exercise. In cases where the “all relevant 
factors” test is applied, the Court does not draw any connection between administrative 
discretion and the precautionary principle; nor does it acknowledge the precautionary nature of 
risk management. In this sense, as the next sub-sections show, it fails to take the prudential 
nature of the relevant risk assessments and the risk manager’s focus on uncertainties and choice 
to resort to a precautionary approach into due consideration. 
Fourthly, this test does not establish clear boundaries for the assessment of compliance with 
the procedural duty to take all relevant factors into consideration; in other words, it is unclear 
what the “relevant factors” may be in the highly complex field of EU risk regulation and in the 
face of scientific uncertainty. This, as shown in sub-section 5.4, affects the consistency of 
application of this standard, given that the relevant procedural elements to be taken into account 
are open to different interpretations.  
Finally, a non-deferential application of this standard of review can catch precautionary 
measures. If the Court does not take a deferential approach, and if it opts for a thorough scrutiny 
of the factors taken (or not taken) into account, this standard of review results in quasi-
substantive scrutiny of the relevant evidence.94 To make some examples, the Court might hold 
that the results of an assessment conducted by means of a specific scientific method, one set of 
data, one body of scientific evidence or the results of an impact assessment are relevant factors 
that the risk manager should have taken into due consideration. This directly encroaches on the 
                                                     
90 Para 35. For the same statement, see first and foremost Case C-269/90, Technische Universität München, para 
14. 
91 Para 29, citing inter alia Case C-269/90, Technische Universität München, EU:C:1991:438, para 14; Case C-
425/08, Enviro Tech I, para 62; and Case C-326/05 P, Industrias Químicas del Vallés v. Commission, 
EU:C:2007:443, para 76. See also para 34, citing Case C-138/79, Roquette, Case C-326/05 P, Industrias Químicas, 
and Case C-425/08, Enviro Tech I. 
92 See the clarification supra in the text of note 74. 
93 Paras. 42 to 50, and 42 and 49 in particular. 
94 See infra sub-section 5.4. 
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risk manager’s discretion in the evaluation of the relevant facts and decision to draw specific 
inferences from the available scientific evidence, in light of the intended level of protection; 
further, it indirectly undermines his ability to enact precautionary risk management measures. 
Indeed, as sub-section 5.4 illustrates, the line between procedural review of administrative 
discretion and quasi-substantive review of the evidence relied upon can be a fine one. The 
acknowledgment of administrative discretion is insufficient to protect precautionary risk 
management; nor can the Court’s deference be taken for granted. 
 
 
5. Following Developments: Coexisting Strands 
 
The following sub-sections take a closer look at the evolution of the Court’s case law, analysing 
relevant cases under four different groups. This overview shows how the Court has differently 
framed the notion of administrative discretion and differently interpreted “manifest” errors of 
assessment, assessing the relevant implications for precautionary risk management. 
The cases in the first group are the ones more closely adhering to the “all relevant factors” 
standard of review. The precautionary principle is barely mentioned in these cases, if at all. 
The Court’s finding that the risk manager did not incur a manifest error of assessment thus 
relies on the (mere) acknowledgment of his broad administrative discretion. The cases in the 
second group are located halfway along the spectrum; the notion of a high level of protection 
and the precautionary principle surface at some point in the analysis, and are not immaterial to 
the Court’s examination. However, the connection between administrative discretion and the 
power to pursue enhanced levels of protection and follow a precautionary approach remains 
implicit. These cases still draw on an application of the “all relevant factors” test. 
The third group of cases draws on Pfizer and Alpharma. In these cases, the Court expressly 
acknowledged the precautionary nature of the measures, drew a clear connection between 
administrative discretion and precautionary risk management, and interpreted the notion of a 
manifest error of assessment in light of the precautionary principle. This effectively safeguards 
precautionary measures. Finally, the cases in the fourth group blur the boundaries between 
procedural and quasi-substantive review; in all cases but one, this has occurred through an 
expansion of review of the risk manager’s duty to take “all relevant factors” into account. As 
illustrated in sub-section 5.4, quasi-substantive review is liable to undermine precautionary risk 
management. 
A further, preliminary clarification is necessary. The specific pleas in law of the applicants or 
the specific questions raised by the referring courts can make it more or less easy for the Court 
to engage with the precautionary principle; clearly, this will be easier if the applicants allege a 
breach or misapplication of the precautionary principle, or if national courts refer specific 
questions surrounding the principle. Perhaps more worryingly, EU institutions themselves are 
too often reluctant to acknowledge their adherence to a precautionary approach to risk 
management.95 However, none of this really prevents the Court from taking the precautionary 
                                                     
95 This emerges clearly from an analysis of cases in the field of chemicals, where EU institutions never refer to 
uncertainties or invoke the precautionary principle; however, an analysis of most cases in the field of pesticides 
also shows that the contested measures rarely – if ever – mention the precautionary principle as their basis. To 
give just one example, see Case T-584/13, BASF Agro and Others v. Commission, EU:T:2018:279, para. 152. 
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principle into account and using it to set the boundaries of (legally relevant) manifest errors of 
assessment.  
There are at least two reasons for this. First, all the cases under analysis involve different forms 
of scientific uncertainty and challenges to acts which are deemed too restrictive. On these 
grounds, all cases involve a focus on persisting uncertainty, adherence to a prudential risk 
assessment and precautionary risk management. Secondly, all cases include complaints or 
questions on manifest errors of assessment or breaches of law. As explained in the previous 
sections, the notion of a manifest error of assessment can (and arguably should) be interpreted 
against the backdrop of the precautionary principle.  
Admittedly, express references to the precautionary principle can be slightly more difficult in 
cases involving “methodological” uncertainties; in these cases, as already explained, scientific 
uncertainty stems from different results obtained through the use of different (more or less 
prudential) methods. Unsurprisingly then, the vast majority of cases on chemicals fall within 
the first group and fail to acknowledge that precautionary risk management measures are at 
stake; these cases relate to scientific methodological aspects. Conversely, it is easier to identify 
the preconditions for the application of the precautionary principle where “hazard-related” or 
“risk-related” uncertainties are at stake. Cases on pesticidal active substances, which involve 
more direct references to absence of scientific proof of a causal link or scientific insufficiency, 
deploy the precautionary principle to a greater extent. 
However, as clearly stated in the Commission Communication, the precautionary principle may 
apply in all cases of scientific uncertainty; it is irrelevant what the specific dimension of 
uncertainty at stake is.96 And indeed, as the Court itself remarked, “the application of the 
precautionary principle is not limited to cases in which it is uncertain that there is a risk; the 
principle may also be applied where a risk has been proved to exist and where the Commission 
must assess whether that risk is acceptable or not […], or assess how it should be dealt with in 
a risk management context […]”.97 Against this backdrop, it is all the more important that the 
Court explicitly addresses the boundaries of scientific uncertainty and precautionary risk 
management in its case law. 
 
 
5.1 “All Relevant Factors” and Administrative Discretion 
 
This line of cases shows a clear focus on administrative discretion, combined with an 
application of the “all relevant factors” test. In the application of this test, the Court took a 
deferential approach; for this reason, these cases have not had an impact on precautionary risk 
management. However, the Court’s findings rely on the mere acknowledgment of the risk 
manager’s broad discretion. No connection is drawn between the notion of administrative 
discretion and the precautionary principle; nor do these cases acknowledge uncertainties or 
recognise the precautionary nature of the relevant risk management measures. 
                                                     
96 For a reference to this point, see supra section 1. And indeed, it is worth stressing that even the original definition 
of the precautionary principle in the Court’s case law, refers to “scientific uncertainty as to the existence or extent 
of risks”. See Case C-157/96, BSE I, paras 63 and 64, and Case C-180/96, BSE II, para 99. 
97 Case T-429/13, Bayer CropScience v. Commission, EU:T:2018:280, para 340, referring to the examination 
carried out in paras. 122, 124 and 125 (hereafter, “Bayer CropScience II”). 
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In Case T-75/06 Bayer CropScience I the applicant sought the annulment of a Commission 
Decision on (non-)inclusion of a pesticidal active substance in the relevant Annex to Directive 
91/414. Under their first plea, the applicants alleged inter alia that the assessment was 
incomplete and based on selective use of the data submitted by the applicant, and that the 
Commission had failed to examine new data provided in response to the newly adopted 
evaluation criteria.98  
As the GC pointed out, the issues at stake in this case boiled down to “whether the Commission 
could legitimately base [its refusal] on the absence of sufficient data” (emphasis added);99 
indeed, the applicants alleged that the Commission had based its evaluation on a zero risk 
threshold, that it had referred to lack of information rather than identified risks, and that it had 
required the applicants to produce a probatio diabolica, proving that the active substance was 
safe.100 All these assertions could have been easily rebutted by framing the notion of a manifest 
error of assessment against the background of the precautionary principle. However, the GC’s 
review of manifest errors was explicitly connected to the examination of whether the 
Commission had examined “all the relevant facts of the case which support the conclusion 
reached”.101 There is no reference to the precautionary principle, the notion of scientific 
uncertainty or hypothetical risk. 
In Enviro Tech I102 the ECJ delivered a preliminary ruling on the validity of the classification 
of n-propyl bromide (“nPB”) as a highly flammable and toxic for reproduction substance. The 
Commission’s classifications were clearly based on results obtained through prudential risk 
assessments; in the face of diverging data and multiple uncertainties, the relevant risks were 
over-estimated and the resulting classification drew on a precautionary approach. The referring 
court asked whether the classification as a highly flammable substance was valid in light of the 
non-application of the assessment criteria enshrined in Directive 67/458; further, it raised 
doubts in so far as the classification as a toxic for reproduction substance had been adopted 
“without clear results in appropriate animal studies where toxic effects have been observed to 
justify a strong presumption that human exposure […] may result in developmental toxicity”, 
and on the basis of tests using a considerably higher concentration of nPB than the one to which 
a person would be exposed when handling the product. The referring court asked whether such 
classifications, which it expressly considered to be based on the precautionary principle rather 
than on the methods and criteria of Directive 67/458, were valid and in compliance with the 
principle of proportionality.103 
In respect of the classification as a highly flammable substance, despite a brief 
acknowledgment of scientific uncertainty,104 the ECJ focused on the broad discretion of EU 
institutions to choose the most appropriate methods of risk assessment.105  It also emphasised 
that the Commission based its findings on a “number of scientific factors […] which permitted 
                                                     
98 Case T-75/06, Bayer CropScience I, cited supra note 74, paras. 72 and 73. The Appeal was dismissed in Case 
C-517/08 P, Makhetshim-Agan Holding and Others v. Commission, EU:C:2010:190. 
99 Para 112. 
100 Para 128. 
101 Case T-75/06, Bayer CropScience I, para 184. 
102 Case C-425/08, Enviro Tech I, cited supra note 74. 
103 Para 28. 
104 Para 61. 
105 Paras. 50 to 55. 
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them to classify that substance in the category […]”. On these grounds, it conducted a review 
of the risk manager’s duty to take all relevant factors into consideration106 and concluded that 
the exercise of the Commission’s classification was not vitiated by a manifest error of 
assessment. Similar considerations were developed on the issue of toxicity for reproduction. 
Yet again expanding the “discretionary powers” element to the detriment of precautionary risk 
management, the ECJ found that a manifest error of assessment had not been incurred. Finally, 
in its joined examination of the precautionary principle and proportionality, the Court found 
that “contrary to the allegations […] the Commission did not base its [classification] on the 
precautionary principle […]”;107 on these grounds, it did not assess the alleged breach of the 
precautionary principle. 
In Case T-291/04 Enviro Tech II,108 the applicants sought the annulment of the very same 
classifications of nPB and damages for alleged non-contractual liability of the EU institutions 
for unlawful conduct. In its review of the alleged manifest errors of assessment the GC drew 
on the ECJ’s decision in Enviro Tech I, again emphasising the Commission’s broad margins of 
administrative discretion to support the finding that it had complied with legislative 
requirements and taken all relevant data into due account.109 This was confirmed on appeal by 
the ECJ.110 
A similar approach can be seen in Cases C-14/10 Nickel Institute111 and C-15/10 Etimine.112 In 
Nickel Institute, the ECJ delivered a preliminary ruling on the validity of the classification of a 
number of nickel-based substances. The referring court asked whether, inter alia, the 
classifications were valid in so far as they were based on tests conducted using the read-across 
method; this choice was challenged by the applicants in front of the national court, on the 
grounds that Directive 67/548 did not provide for use of this method.  
The Court justified the use of the read-across method by reference to the latter’s inclusion in 
other legislative instruments, by emphasising the non-exhaustive nature of the list of sources 
from which data may be extracted, and by stressing the complementarity of different scientific 
methods.113 In so far as the applicants claimed that, even if recourse to this method was 
permissible, its application in the present case was manifestly flawed, the Court drew on the 
risk manager’s broad discretion to conclude that these arguments did “not in themselves permit 
the view to be taken that the Commission […] manifestly exceeded the limits of its 
discretion”.114 The focus is clearly on the notion of administrative discretion, without any 
acknowledgment of the risk manager’s discretionary power to take into account the results of 
prudential risk assessments.  
                                                     
106 Paras. 62 to 64. 
107 Para 74. The Commission, which also focused on its broad administrative discretion, contended that the 
classification was “in no way based […] solely on the precautionary principle” (emphasis added); see para 44. 
108 Case T-291/04, Enviro Tech Europe and Enviro Tech International v. Commission, EU:T:2011:760 (hereafter, 
“Enviro Tech II”). 
109 Para 157. 
110 Case C-118/12, Enviro Tech Europe v. Commission, EU:C:2013:37. 
111 Case C-14/10, Nickel Institute, EU:C:2011:503. 
112 Case C-15/10, Etimine, EU:C:2011:504. 
113 Paras. 62 to 75. 
114 Para 77. 
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Among the most recent cases in this strand, we find T-400/17 Deza II.115 In this case the 
applicant pointed to the absence of conclusive evidence establishing a causal link between the 
ingestion of anthraquinone and the carcinogenic effects observed in laboratory tests; 
uncertainty persisted as to what extent carcinogenic effects were connected to exposure to this 
substance. In its examination of the various points raised by the applicants, the GC merely 
found that they had failed to prove that EU institutions had not taken all relevant factors into 




5.2 “All Relevant Factors”, Administrative  Discretion and a High Level of 
Protection 
 
This strand of case law draws on procedural review of the duty to take all relevant factors and 
circumstances into account; the notion of a manifest error of assessment is not interpreted in 
light of the precautionary principle. However, a careful analysis of these cases shows that the 
notion of a high level of protection and the precautionary principle are not immaterial to the 
Court’s examination. Rather, the connection between administrative discretion and the risk 
manager’s power to draw on a precautionary approach remains implicit, as the relevant notions 
and implications are not fleshed out.  
In Case T-93/10 Bilbaína I116 the applicants sought the partial annulment of the ECHA’s 
decision to identify CTPHT as a substance meeting the criteria laid out in Article 57 REACH. 
By their second plea, the applicants claimed an error of assessment or error of law in so far as 
the identification of CTPHT as a substance with persistent, bioaccumulative and toxic (“PBT”) 
and very persistent and very bioaccumulative (“vPvB”) properties resulted from the application 
of the summation method, which involves an assessment of the properties of the constituents 
of the substance rather than an assessment of the properties of the substance. The applicants 
complained that the ECHA’s dossier did not observe the requirements of REACH because the 
summation method is not laid down in the Annexes to the Regulation.117 
The GC found that, given that “the constituents of a substance are an integral part of it, it cannot 
simply be held that the ECHA made a manifest error of assessment in taking the view that 
[CTPHT] had PBT and vPvB properties on the grounds that its constituents had such 
                                                     
115 Case T-400/17, Deza v. Commission, EU:T:2018:712 (“Deza II”), under appeal. 
116 Case T-93/10, Bilbaína de Alquitranes and Others v. ECHA, EU:T:2013:106 (“Bilbaína I”). See also Case T-
94/10, Rütgers Germany and Others v. ECHA, EU:T:2013:107; Case T-95/10, Cindu Chemicals and Others v. 
ECHA, EU:T:2013:108; and Case T-96/10, Rütgers Germany and Others v. ECHA, EU:T:2013:109. The Appeals 
were respectively dismissed in Case C-287/13 P, Bilbaína de Alquitranes and Others v. ECHA, EU:C:2014:599; 
Case C-288/13 P, Rütgers Germany and Others v. ECHA, EU:C:2014:2176; Case C-289/13 P, Cindu Chemicals 
and Others v. ECHA, EU:C:2014:2175; and Case C-290/13 P, Rütgers Germany and Others v. ECHA, 
EU:C:2014:2174.. 
117 Case T-93/10, Bilbaína I, para 74. The applicants also alleged that the assessment of the constituents at issue 
did not provide a sufficient basis to identify CTPHT as a substance having PBT and vPvB properties, on the 
grounds that none of the constituents besides anthracene had been individually identified as having PBT and vPvB 
properties and that, in the case of anthracene, the 0.1% threshold had not been met. The Court found that they had 
failed to prove a manifest error of assessment in this respect. 
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properties”.118 Notably, the GC remarked that the opposite conclusion would “not take 
sufficient account of the objective pursued by [REACH], […] which is to ensure a high level 
of protection of human health and the environment […]” (emphasis added).119 Against this 
backdrop, drawing on the technical-scientific reasons adduced by the ECHA and on a 
teleological interpretation of REACH, the GC found that whilst an application of the 
summation method was not expressly indicated in the Regulation, the latter did “not preclude 
such approach”.120  
The GC then engaged in a thorough procedural analysis of the points raised by the applicants, 
with a view to ascertaining whether the ECHA had taken all relevant factors into consideration 
in the application of the summation method. Importantly, it noted that assessing hazardous 
substances on the basis of their constituents allows for an analysis of how the constituents will 
behave as independent substances in the environment and release hydrocarbons with PBT or 
vPvB properties. By contrast, the study of a substance as a whole does not lead to significant 
results in this respect. The physical form of the substance may impede the release of the 
constituents in laboratory tests; however, in reality, the single constituents will release 
hydrocarbons with PBT or vPvB properties in the environment after a certain time.121  
Clearly, the choice to resort to the summation method drew on a prudential approach to risk 
assessment, whose results then fed into precautionary risk management. However, despite its 
initial reference to the notion of a high level of protection, the GC did neither mention scientific 
uncertainty, nor the prudential nature of this risk assessment. In a different vein, it underlined 
that the substance “was not identified as having PBT and vPvB properties solely because a 
constituent of that substance has a certain number of PBT and vPvB properties, but that the 
proportion in which such a constituent is present and the chemical effects of the presence of 
such a constituent were also taken into account […]”;122 in other words, it focused on the 
procedural duty to take all factors into account and found that, in this respect, the decision was 
not vitiated by a manifest error of assessment. 
A similar focus on procedural factors, combined with references to a high level of protection 
and the precautionary principle, emerges from an analysis of Case T-368/11 Polyelectrolyte.123 
In this case the applicants challenged various restrictions on Acrylamide. The applicants 
claimed that, in its evaluation of risks, the Commission had failed to take account of all relevant 
factors and incurred a manifest error; more specifically, they alleged that the information relied 
upon did neither relate to exposure arising from uses of acrylamide that are known or 
reasonably foreseeable, nor to uses to which humans would be likely to be exposed.124 Again, 
the GC conducted a thorough procedural review. Among its complaints, the applicants raised 
the point that the Commission had made a manifest error of assessment by drawing on 
information on exposure scenarios that were not known or reasonably foreseeable in the EU, 
                                                     
118 Para 83. 
119 Ibid. 
120 Para. 83. 
121 Paras. 90 and 91. 
122 Para 100. 
123 Case T-368/11, Polyelectrolyte Producers Group and Others v. Commission, EU:T:2013:53. The Appeal was 
dismissed in Case C-199/13 P, Polyelectrolyte Producers Group and Others v. Commission, EU:C:2014:205. 
124 Para 25. 
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i.e. not representative.125 The GC examined whether, in relying on data about worst-case 
scenarios, the Commission had incurred a manifest error of assessment. On the one hand, it 
noted that the pursuit of a high level of protection and the precautionary principle are enshrined 
in the Treaties and in relevant legislation, so that the Commission was entitled to take into 
consideration these data.126 On the other hand, the GC’s review of the duty to take all relevant 
factors at stake is still at the heart of the examination; in this respect, it found that although the 
EU risk assessment report took account of the worst case scenario, it also took into 
consideration the normal conditions of use.127 Ultimately, this is the basis and justification for 
the final finding that the decision was not vitiated by a manifest error.128 
 
 
5.3 Reconnecting Manifest Errors of Assessment, Administrative Discretion 
and Precautionary Risk Management 
 
The cases in this group follow the Pfizer and Alpharma line of reasoning, wherein the analysis 
of manifest errors of assessment is set against the backdrop of the notions of scientific 
uncertainty (as opposed to hypothetical risk), precautionary risk management and the 
overarching tenets of the precautionary principle. In some of these cases, complaints alleging 
a failure to take all relevant factors into account and complaints on manifest errors of 
assessment in scientific matters are kept distinguished; in the analysis of the latter complaints, 
the Court largely resorted to the precautionary principle. In other cases, review of whether the 
risk manager took all relevant factors into account is ultimately absorbed in the Court’s review 
of manifest errors of assessment in scientific matters; the latter form of review is explicitly set 
against the background of the precautionary principle. 
Overall, in all cases in this strand, the Court did not quite focus on checking whether the 
procedural preconditions for the risk manager’s exercise of discretion had been complied with 
(the “all relevant factors” test). Rather, like in Pfizer and Alpharma, it drew a clear association 
between administrative discretion and precautionary risk management. Review of compliance 
with proportionality is analysed separately, having regard to the risk management measures at 
issue rather than their scientific substantiation.129  
Case T-392/02 Solvay, another case on the withdrawal of additives used in animal feed, mirrors 
Pfizer and Alpharma. The applicants alleged, inter alia, breaches of law, manifest errors and 
misapplication of the precautionary principle, in so far as they claimed that the withdrawal was 
based on a purely hypothetical approach to risk.130 The GC closely followed the line of 
reasoning in the “twin” Pfizer and Alpharma cases, interpreting the notion of a manifest error 
                                                     
125 Para 50. 
126 Para 62. 
127 Para 59. 
128 For another example, see Case T-115/15, Deza v. ECHA, EU:T:2017:329 (“Deza I”). The Appeal was 
dismissed in Case C-419/17 P, Deza v. ECHA, EU:C:2019:52. 
129 In this strand, see also Case T-201/13, Rubinum v. Commission, EU:T:2015:311, and the Opinion of A.G. 
Mengozzi in Case C-680/16, August Wolff and Remedia v. Commission, EU:C:2018:819. 
130 Case T-392/02, Solvay Pharmaceuticals v. Council, EU:T:2003:277, para 27. The case was not appealed. 
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of assessment against the broader backdrop of persisting uncertainty and precautionary risk 
management.131  
In Case T-326/07 Cheminova the applicants sought the annulment of a 2007 Commission 
Decision on the (non-)inclusion of an active pesticidal substance in the relevant Annex to 
Directive 91/414. The applicants complained, inter alia, that the Commission had failed to take 
into account all information, data and studies, so that its finding that scientific information was 
insufficient was unsubstantiated,132 and that the decision was not based on the latest science.133 
After an examination of whether all data provided by the applicants had been taken into 
account, the GC ultimately based its reasoning on the precautionary principle134 and concluded 
that “the applicants have not shown that the evidence available to the Commission would have 
dispelled all reasonable doubt as to malathion’s harmful effects”.135 The same occurred in Case 
T-71/10 Xeda, which also regarded the withdrawal of authorisation for a pesticidal active 
substance. The applicants challenged the EFSA’s conclusion that a number of concerns 
remained and that it was impossible to perform a reliable exposure assessment, due to the 
absence of data or insufficiency of the available data, again arguing that this conclusion rested 
on a hypothetical approach to risk.136 The conclusion of the GC’s assessment, conducted in 
light of the precautionary principle,137 was that the applicant had not proven any manifest errors 
of appraisal.138 Similar considerations apply to T-31/07 Du Pont de Demours, where the 
applicant also sought damages and the GC engaged in a thorough analysis of the boundaries of 
precautionary risk management.139 
However, the triad of cases which best mirrors the “twin” decisions in Pfizer and Alpharma 
consists of Dow Agrosciences,140 Sepro Europe141 and Bayer CropScience II.142 All these cases 
involved challenges to withdrawals of authorisations for pesticidal active substances. In Dow 
Agrosciences, like in previous cases, the applicants challenged the Commission’s departure 
from the positive results of the EFSA’s risk assessment; the GC rejected this line of 
argument.143 Further, they alleged manifest errors of assessment in that the Commission had 
not taken all factors into account144 and its findings were not scientifically substantiated.145 Part 
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132 Case T-326/07, Cheminova and Others v. Commission, EU:T:2009:299, para 94 (not appealed). 
133 Paras. 158 et seq. 
134 Para 166. 
135 Para 171. 
136 Case T-71/10, Xeda International and Pace International v. Commission, EU:T:2012:18, paras. 64 et seq. The 
Appeal was dismissed in Case C-149/12 P, Xeda International and Pace International v. Commission, 
EU:C:2013:433. 
137 Paras. 69 to 78. 
138 Para 120. 
139 Case T-31/07, Du Pont de Demours (France) and Others v. Commission, EU:T:2013:167, paras. 128 to 150 
and 151 to 214 (not appealed). 
140 Case T-475/07, Dow Agrosciences and Others v. Commission, EU:T:2011:445. The Appeal was dismissed in 
Case C-584/11 P, Dow Agrosciences and Others v. Commission, EU:T:2013:281.  
141 Case T-483/11, Sepro Europe, EU:T:2013:407 (not appealed). 
142 Case T-429/13, Bayer CropScience II, cited supra note 97. 
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of the analysis of whether all factors had been taken into consideration was absorbed in the 
GC’s review of the scientific substantiation of the measures, against the backdrop of the notion 
of precautionary risk management.  
Moreover, in this case, the GC added a further specification. After an analysis of the 
precautionary principle and political role of EU risk managers in the determination of the 
threshold of acceptable risk,146 it held that “in order to establish that the Commission committed 
a manifest error of assessment […] such as to justify the annulment of a decision […] the 
[scientific] evidence adduced by the applicant must be sufficient to make the factual 
assessments used in the decision implausible” (emphasis added).147 This reference to 
“implausibility” bears a close resemblance to the finding of Advocate General Jääskinen in 
Case C-77/09 Gowan that risk management measures could only be rendered invalid by 
flagrant inconsistency with a risk assessment “based on an undisputed methodology leaving no 
room for scientific uncertainty”.148 Gowan, a preliminary ruling on the validity of restrictions 
on a pesticidal active substance, also involved a decision departing from the positive results of 
a risk assessment.149 However, in Dow Agrosciences, this finding is more clearly and explicitly 
set in the context of precautionary risk management. The procedural analysis of the Opinion in 
Gowan, on the other hand, set the notion of manifest error of assessment and “flagrant 
inconsistency” against the background of the risk manager’s broad discretionary powers.150 
The centrality of the of the precautionary principle is even clearer in Sepro Europe.151 Finally, 
in Bayer CropScience II, the GC powerfully reasserted the connection between the 
interpretation of manifest errors of assessment and the need to safeguard precautionary risk 
management. The amendment of the conditions of approval of neonicotinoids, highly 
controversial pesticidal active substances, was at stake in this case. The GC conducted a 
thorough preliminary analysis of the precautionary principle,152 technical-scientific risk 
assessment,153 the determination of the level of risk deemed unacceptable,154 risk 
management,155 the burden of proof156 and the scope of judicial review,157 including a reference 
to the “plausibility” criterion mentioned in Dow AgroSciences.158  
                                                     
146 Paras. 143 et seq. 
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It is in this light that the GC examined all the applicants’ complaints on alleged manifest errors 
of assessment, including the failure to take all relevant studies and data into due consideration, 
under the umbrella of the precautionary principle and scientific uncertainty. Just like in Pfizer 
and Alpharma, the complaints alleging manifest errors of assessment and those alleging 
misapplication of the precautionary principle were examined together. Indeed, with 
unprecedented clarity, the GC stated in paragraph 336 that “the answer to the question whether, 
given the Commission’s discretion in relation to risk management, certain scientific knowledge 
and information supported the conclusion that the conditions of approval were no longer 
satisfied and that the approval of the substances covered had to be amended is […] influenced 
by the precautionary principle”.159 This is the clearest possible acknowledgment of the need 
to draw a connection between the notions of manifest error of assessment, political-
administrative discretion, scientific uncertainty and precautionary risk management; this is 
what the Court did in this case, rejecting the applicants’ complaints one by one.  
 
 
5.4 From Procedural Review of “All Relevant Factors” to Quasi-Substantive 
Review 
 
This final sub-section analyses cases where the Court has applied a quasi-substantive standard 
in its review of EU precautionary measures challenged by the applicants for being too 
restrictive.160 This standard, which crosses the fine line between procedural and substantive 
review, is “quasi-substantive” in a twofold sense. First, it expands on review of compliance 
with the procedural preconditions for the exercise of administrative discretion. In this sense, it 
cannot be properly defined as a “substantive” standard. Secondly, it is “quasi-substantive” in 
its effects. As the analysis shows, the Court’s scrutiny of the evidence relied upon by the risk 
manager and its examination of whether it was taken into due consideration in the final decision 
might indirectly constrain administrative discretion. The suggestion that specific assessments 
should be conducted or specific factors should be taken into account pertains to the relevant 
procedural obligations of the risk manager; the Court does not directly pick and choose the 
evidence which should substantiate the final measures, nor does it conclude that conducting 
certain assessments or taking some evidence into account should result in a specific regulatory 
measure. However, employing a quasi-substantive standard may indirectly yield the same 
result. This is liable to impact on precautionary risk management.  
Artegodan, the first case under analysis in this section, may in its own right be defined as the 
only instance of “substantive” review of the scientific evidence underlying risk management 
measures; under a different reconstruction, the GC simply found that the measures at stake 
                                                     
159 Para 336. 
160 This section does not examine cases where acts deemed too restrictive where annulled for procedural breaches 
which are ultimately unrelated to the evidence procedurally relied upon; examples are Case T-125/96, Boheringer 
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were in breach of proportionality. ICdA, BASF and Bilbaína II, on the other hand, exemplify 
the impact of a non-deferential application of the “all relevant factors” test. In these cases, the 
Court drew on the “all relevant factors” standard to conduct an intrusive examination of the 
relevant evidence.  
In Artegodan, the applicants sought the annulment of a string of Commission Decisions on the 
withdrawal of marketing authorisations for medicinal products containing a range of anorectic 
agents. Despite the inability to establish a causal link, use of these anorectic agents had long 
been associated with a range of uncertain health risks; in this respect, no new scientific evidence 
had become available since the original authorisations. However, “accumulated scientific 
knowledge acquired over the years”161 had proven that the therapeutic efficacy of these 
substances was very limited. On these grounds, drawing on the Opinion of the relevant 
Scientific Committee, the Commission determined that the risk/benefit balance was no longer 
positive and withdrew the authorisations.162  
The GC argued that the precautionary principle requires withdrawal of an authorisation “where 
new data give rise to serious doubts as to either the safety or the efficacy of the medicinal 
product in question and those doubts lead to an unfavourable assessment of the benefit/risk 
balance of that medicinal product”.163 After this acknowledgment, quite surprisingly, it found 
that the Committee’s Opinion did not make any reference to “new scientific data or information 
which […] would explain the development of [medical] consensus”164 and concluded that 
changes in clinical and therapeutic practices could not justify the withdrawals in the absence 
of new scientific evidence.165 
This decision lends itself to a twofold reading. If regard is had to the GC’s finding that the 
development of medical consensus cannot qualify as “new” scientific evidence, Artegodan 
exemplifies the impact of a substantive standard of review. Ultimately, the GC scrutinised the 
“quality” of the scientific data underlying the measures and selected the specific type of 
scientific evidence that the Commission could rely upon. In the face of persisting uncertainty 
on the health risks posed by anorectic agents, and in light of the re-assessment of their benefits, 
the Commission had clearly taken the view that their use no longer met the threshold of 
acceptable risk. The GC’s decision directly impacted on this – discretionary and precautionary 
– evaluation.  
An alternative reading suggests that, while pointing to the “novelty” of the relevant scientific 
evidence, the GC in fact tacitly scrutinised whether the measures complied with the principle 
of proportionality. From this different angle of analysis, the GC targeted the risk management 
measures and the level of protection that the measures pursued. Under this reconstruction, the 
GC implicitly suggested that the withdrawals were in breach of proportionality. Ultimately, 
this does not change the final result. As argued in the second section, and as this case arguably 
shows, proportionality review will still encroach on the determination of the intended level of 
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protection and lower it. Artegodan has remained an isolated “anomaly” in the case law of the 
Court.166 
In a different vein, International Cadmium Association (“ICdA”)167 shows an expansion of the 
Court’s review under the “all relevant factors” test. While the GC nominally followed a 
procedural standard of review, the effects are quasi-substantive in nature. This case involved a 
challenge to a 2011 amendment to Annex XVII (Cadmium) of REACH. By this amendment, 
cadmium and its compounds (including cadmium pigments) could no longer be used in articles 
or mixtures produced from plastic;168 this significantly expanded the pre-existing restrictions, 
extending their scope from mere restrictions on use in PVC to encompass use in all plastic 
materials.169 The GC annulled the Commission Regulation on the grounds of an alleged failure 
to take into due consideration the behaviour of cadmium pigments (as opposed to cadmium) in 
plastic materials (as opposed to the more circumscribed case of PVC). In this sense, the GC 
allegedly applied a procedural standard of review, pointing to a procedural failure to conduct 
an individual risk assessment and thus concluding that the Commission had incurred a manifest 
error.  
Yet, a careful analysis of the case shows that the Commission had adduced some evidence on 
the behaviour of cadmium pigments in all plastic materials. For instance, the Commission 
referred to a 2000 report identifying a link between the presence of cadmium in the 
environment, on the one hand, and the incineration of (any kind of) plastic containing cadmium 
pigments, or leaching of plastic waste from incinerators, on the other. In a similar vein, the 
Commission relied on a further study on the behaviour of cadmium and cadmium pigments in 
landfills. However, the GC found that these studies could not reach specific conclusions as to 
the precise sources of cadmium detected in landfills,170 including the presence of cadmium 
pigments in plastic materials other than PVC.171 In other words, the GC found that these 
scientific studies were not sufficiently cogent or specific. 
The standard of scrutiny employed in ICdA crosses the line between procedural review of 
compliance with the obligation to take all factors into account, and substantive review of the 
quality and specificity of the scientific evidence relied upon. Cadmium and its pigments are 
non-threshold carcinogens and pose high public health and environmental risks; in light of 
exposure from multiple sources (waste incineration and landfills, steel production, oil and coal 
combustion, traffic), the measure challenged in this case was part of a broader EU risk 
reduction strategy. Clearly, technical difficulties may come into play if specific evidence on 
the behaviour of cadmium pigments in each and every type of plastic disposed of in landfills 
or incinerated is to be provided. Would it be possible at all to conduct as specific a risk 
assessment as the GC suggested? If this proved impossible, by requesting a specific standard 
for the scientific substantiation of the measures, the GC would indirectly limit the risk 
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manager’s discretionary choice to enact precautionary measures in a case involving a highly 
hazardous substance. As already explained, this is typical of quasi-substantive review. 
In BASF,172 on the other hand, the applicants challenged a Regulation amending the conditions 
of approval for the pesticidal active substance fipronil. The applicants alleged a misapplication 
of the precautionary principle173 in so far as the Commission had not conducted an impact 
assessment, analysing the economic costs and benefits of alternative risk management options, 
as allegedly mandated by point 6.3.4 of the Communication on the Precautionary Principle.174 
The GC noted that the Communication does not specify the format or scope of the evaluation 
of any advantages and disadvantages associated with risk management measures; in particular, 
the risk manager does not appear to be under an obligation to produce a written assessment 
report.175 The GC thus remarked that the requirements of the Communication are satisfied 
where the authority concerned has “[…] acquainted itself with the effects, positive and 
negative, economic and otherwise, to which the proposed action […] may lead”.176 However, 
it also added that the corollary of the discretion conferred on the administration is an obligation 
to exercise that discretion by taking all relevant factors into consideration;177 on these grounds, 
it found that the Commission “was obliged, pursuant to the precautionary principle, to carry 
out an impact assessment” (emphasis added).178 After this preliminary examination, the GC 
went on to assess whether the Commission had conducted such analysis. It found that absence 
of any written record of an impact assessment suggested that such assessment had not been 
carried out at all.179 It thus annulled the Commission’s Regulation.  
As the GC rightly noted in this case, the obligation to carry out an impact assessment is “no 
more than a specific expression of the principle of proportionality”.180 Review of compliance 
with the obligation to conduct an impact assessment or review of whether risk managers have 
taken all relevant data into consideration would not be problematic if the Court were to adopt 
a deferential standard; however, they could be highly problematic if this were not the case. 
Arguably, it is not by mere coincidence that the Court’s traditionally deferential approach to 
proportionality review in EU risk regulation has gone hand in hand with a soft approach to the 
risk manager’s duty to conduct an impact assessment. Further, the Court has stressed in its case 
law that the results of an impact assessment do not bind the risk manager.181 
On these grounds, an obligation to conduct an impact assessment, produce some proof thereof 
and reference relevant data and evaluations exposes the risk manager to the possibility of more 
intense proportionality review. In this very sensitive field, this could be problematic. Against 
this overall backdrop, the mere “procedural” findings of BASF are liable to have a quasi-
substantive impact; on these grounds, this case qualifies under the quasi-substantive standard 
of review group of cases. 
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Finally, in Bilbaína II,182 the Court took an unprecedented stance on the risk manager’s duty to 
take all relevant factors into consideration, crossing the line between procedural and 
substantive review more clearly than ever before. Like in ICdA, the Court’s standard of scrutiny 
in Bilbaína II has expanded on the “all relevant factors” test. Yet, in Bilbaína II, the Court did 
not merely suggest that the relevant risk assessment was insufficiently cogent. Rather, it 
pointed to the Commission’s failure to take one specific factor into due consideration for the 
purposes of its final decision.  
In Case T-689/13183 the applicants challenged the classification of CTPHT as an aquatic acute 
1 and aquatic chronic 1 substance under the CLP Regulation. More specifically, just like in 
Bilbaína I, they alleged a manifest error of assessment in so far as the Commission had referred 
to the results of risk assessments conducted through the – prudential – summation method; this 
method provides a calculation of the toxicity effects of the single constituents, resulting in an 
over-estimation of the relevant risks.184 The applicants claimed that the Commission had 
disregarded the fact that the components of CTPHT, when bound together in the substance, 
have a very low level of water solubility and bio-availability. Taking this factor into account 
would have had the same effect as applying a different method, based on a calculation of the 
aquatic toxicity effects of the substance as a whole and yielding very different results. In fact, 
the Commission had relied on the ECHA’s finding that uncertainties persist as to the behaviour 
of the individual constituents of CTPHT when in contact with water. This led to the application 
of the summation method. 
The GC found that the Commission had failed to comply with its obligation to take into 
consideration all the relevant factors and circumstances of the case, incurring a manifest error 
of assessment.185 Specifically, it pointed to the Commission’s failure to take into consideration 
the stability and the low level of water solubility of the substance as a whole.186 It thus 
concluded that the Commission had incorrectly applied the summation method.  
Unsurprisingly, the Commission complained on appeal that the GC had violated its duty to 
state reasons and erred in law in annulling the Regulation because of the use of the summation 
method or, alternatively, because of its incorrect application;187 as the Commission pointed 
out, taking the stability and solubility of the whole substance into consideration when applying 
the summation method was tantamount to applying a different method. Moreover, the 
Commission maintained that the GC had exceeded the limits of judicial review, going beyond 
the review of a manifest error of assessment.188 Both Advocate General Bobek189 and the ECJ 
took the view that the GC had neither erred in law,190 nor exceeded the limits of judicial review. 
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On the latter point, they ultimately concurred that the Judgment did not imply “that, if the 
Commission had taken the solubility of CTPHT as a whole into account, [this] would have 
inevitably trumped all other factors”191 or resulted in a different classification of CTPHT. 
Bilbaína II is hard to reconcile with Bilbaína I, where the GC and the ECJ found that the 
Commission was entitled to use the summation method and had taken all relevant factors into 
consideration in its application;192 the very same method was at stake in both Bilbaína I and II. 
Notably, the substance at issue (and most of the applicants) were also the same in the two cases. 
This shows the potential inconsistency of the “all relevant factors” test, in so far as the 
boundaries and nature of the “relevant” factors to be taken into account are open to 
interpretation. 
More importantly, however, Bilbaína II perfectly epitomises the blurred boundaries between 
procedural review of whether all relevant factors have been taken into account, on the one hand, 
and substantive review of the “quality” and “soundness” of the scientific evidence relied upon, 
on the other. Both the Advocate General and the ECJ maintained that the findings of the GC 
related to procedural aspects, rather than the substance of the final decision. Under this 
reconstruction, the Judgment would not encroach on the risk manager’s discretion in the 
enactment of precautionary risk management measures. Yet, it is hard to see how the 
Commission could comply with its duty to take the characteristics of CTPHT as a whole 
substance into due consideration when applying the summation method. Ultimately, as the 
Commission argued, this implies the application a different method; the application of a 
different method, in turn, will yield different results and result in a different – non-
precautionary – classification. Against this backdrop, the discretion of the risk manager is 
indirectly bound and precautionary risk management is undermined.  
As this case shows, the expansion and non-deferential application of the “all relevant factors” 
test poses considerable challenges to the application of the precautionary principle. Bilbaína II 
might then turn out to be a sign of a structural problem, rather than an isolated deviation from 
the traditional standard of review. 
 
 
6. Conclusions: from Proportionality and “All Relevant Factors” to a 
Greater Role for the Precautionary Principle 
 
This article has conducted an analysis of challenges to EU precautionary risk management 
measures, enquiring to what extent the Court’s application of different standards may safeguard 
precautionary risk management and do justice to the key role and function of the precautionary 
principle. The analysis has identified two problematic aspects. 
First, the overlapping analysis of the precautionary principle and proportionality in preliminary 
rulings does not do justice to the rationale for precautionary risk management, the aims pursued 
by the risk manager and the key role of the precautionary principle in EU risk governance. In 
cases where scientific uncertainty and a “stricto sensu” application of the precautionary 
principle are at stake, a contextual analysis of the two principles fails to address the scientific 
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dimension in which the precautionary principle is embedded, the relevance of different forms 
of uncertainty and the pursuit of a high level of protection. Arguably, as noted in the fourth 
section, the analysis of the precautionary principle becomes “ancillary” to proportionality 
review. For this reason, as suggested in the second section, alleged breaches or misapplication 
of the precautionary principle should be examined autonomously, or in conjunction with 
questions surrounding manifest errors of assessment. 
Secondly, in the context of direct actions for annulment, different strands of case law have 
differently framed the notion of administrative discretion and provided a different 
interpretation of legally relevant manifest errors of assessment. The Pfizer and Alpharma line 
of cases draws a clear connection between administrative discretion and precautionary risk 
management, emphasising that the risk manager is exercising his power to enact precautionary 
measures. Symmetrically, as the third and fifth sections have illustrated, the notion of a 
manifest error of assessment is interpreted against the background of the precautionary 
principle. Precautionary measures are thus effectively safeguarded. Further, the Court’s 
approach in this line of cases is more faithful to the rationale and overarching tenets of the 
precautionary principle, and reflects the institutional architecture of EU risk regulation.  
By contrast, different strands of case law put the accent on (mere) administrative discretion. In 
these cases, the precautionary principle is hardly mentioned; a manifest error is associated with 
the risk manager’s failure to procedurally take all relevant factors into account. This failure to 
acknowledge the precautionary nature of risk management measures is hard to reconcile with 
the centrality of the precautionary principle under EU risk regulation. Further, as the fourth and 
fifth sections have demonstrated, the “all relevant factors” test is associated with a number of 
problems. Most importantly, a non-deferential application of this test can indirectly threaten 
precautionary risk management, resulting in quasi-substantive review and thus undermining 
the risk manager’s power to take precautionary action. The mere acknowledgment of the risk 
manager’s discretion is insufficient to safeguard precautionary risk regulation. 
On these grounds, the Court’s different framing of the notion of administrative discretion and 
its different interpretation of manifest errors of assessment is by no means a mere issue of form 
or terminology. Rather, it has substantive implications. For this reason, it is all the more 
important that the Court follows the Pfizer and Alpharma strand of procedural review. The 
Court should always draw an explicit connection between administrative discretion and 
precautionary risk management; further, and crucially, it should always interpret the notion of 
a legally relevant manifest error of assessment in light of the precautionary principle. 
As explained in the second section, EU institutions are neither bound to adhere to “sound” 
science, nor to refer to economic cost-benefit analysis and the results of impact assessment. At 
a minimum, EU institutions are fully entitled to take the precautionary principle into due 
consideration. Under a “maximalist” interpretation, the principle is an “inner limit” to the risk 
manager’s discretion. The complementarity of technical expertise and democratic legitimacy 
and the latter’s superiority shine through the precautionary principle. The principle enshrines a 
right to focus on ubiquitous uncertainties, with a view to pursuing enhanced levels of 
protection. In the face of scientific complexity, scientific pluralism and the evolutionary nature 
of scientific research, this is a perfectly legitimate regulatory choice; nor is recourse to the 
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precautionary principle, by any means, a-scientific.193 The principle also suggests that 
collective public health and environmental stakes194 should prevail over individual – trade and 
market access – rights, or at least be taken into due consideration. All of this lies at the heart of 
the notions of “intended level of protection” and “threshold of acceptable risk”. 
Against this backdrop, the Court’s case law should closely focuses on scientific uncertainty 
and the underlying tenets of the precautionary principle. In direct actions for annulment, the 
notion of a manifest error of assessment should always be interpreted in light of the 
precautionary principle. In preliminary rulings, the examination of the principle should not be 
“ancillary” to proportionality review. Precautionary risk management would then be 
effectively safeguarded, and the crucial role and value of the precautionary principle as a 
general principle of EU law would be more clearly and more fully acknowledged. 
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